Publikationen Team Weiskirchen

* Abu Jhaisha S, Hohlstein P, Yagmur E, Köller V, Pollmanns MR, Adams JK, Wirtz TH, Brozat JF, Bündgens L, Hamesch K, Weiskirchen R, Tacke F, Trautwein C, Koch A. Soluble Semaphorin 4D serum concentrations are elevated in critically ill patients with liver cirrhosis and correlate with aminotransferases. In: Diagnostics, 2024, 14:370.

* Buniatian GH, Schwinghammer U, Tremmel R, Cynis H, Weiss TS, Weiskirchen R, Lauschke V, Youhanna S, Ramos I, Valcarcel M, Seferyan T, Rahfeld J.U., Rieckmann V, Klein K, Buadze M, Weber V, Kolak V, Gebhardt R, Friedman SL, Müller U, Schwab M, Danielyan L. Consequences of amyloid-β deficiency for the liver. In: Adv Sci, 2024, 11, 202307734.

* Chaudhary R, Goodman LS, Wang S, Asimakopoulos A, Weiskirchen R, Dooley S, Ehrlich M, Henis YI. Cholesterol modulates type I-type II TGF-β receptor complexes and alters the balance between Smad and Akt signaling in hepatocytes. In: Commun Biol, 2024, 7:8.

* Chandrasekaran P, Weiskirchen R. The pivotal role of MBOAT7 in non-alcoholic fatty liver disease. In: Livers, 2024, 4, 1-14.

* Chandrasekaran P, Weiskirchen R. Cellular and molecular mechanisms of insulin resistance. In: Curr Tissue Microenviron Rep, 2024, in press. doi: 10.1007/s43152-024-00056-3

* Chandrasekaran P, Weiskirchen R. Role of SCAP/SREBP in hepatic steatosis. In: Encyclopdia. Available at: https://encyclopedia.pub/entry/history/show/122398.

* Chandrasekaran P, Weiskirchen R. The role of obesity in type 2 diabetes mellitus – An overview.In: Int J Mol Sci, 2024, 25:1882.

* Chandrasekaran P, Weiskirchen R. The role of SCAP/SREBP as central regulators of lipid metabolism in hepatic steatosis. In: Int J Mol Sci, 2024, 25:1109.

* Hohlstein P, Abu Jhaisha S, Yagmur E, Wawer D, Pollmanns MR, Adams JK, Wirtz TH, Brozat JF, Bündgens L, Hamesch K, Weiskirchen R, Tacke F, Trautwein C, Koch A. Elevated Midkine serum levels are associated with long-term survival in critically Ill patients. In: Int J Mol Sci, 2024, 25:454.

* Krizanac M, Mass Sanchez PB, Weiskirchen R, Schröder SK. Overview of the expression patterns and roles of Lipocalin 2 (LCN2) in the reproductive system. In: Front Endocrinol, 2024, 15:1365602.

* Lammert FC, Pannhausen J, Noetzel E, Friedland F, Witz J, Herfs Y, Leypold S, Gan L, Weiskirchen R, Schnitzler T, Knüchel R, Maurer J, Jonigk DD, Rose M, Gaisa NT. Dual role of GRHL3 in bladder carcinogenesis depending on histological subtypes. In: Mol Oncol, 2024, in press. doi: 10.1002/1878-0261.13623

* Mass-Sanchez PB, Krizanac M, Stancl P, Leopold M, Engel K, Buhl EM, van Helden J, Gaßler N, Schiller J, Karlic R, Möckel D, Lammers T, Meurer SK, Weiskirchen R, Asimakopoulos A. Perilipin 5 deletion protects against nonalcoholic fatty liver disease and hepatocellular carcinoma by modulating lipid metabolism and inflammatory responses. In: Cell Death Discov, 2024, 10(1):94.

* Makowska A, Kontny U, Weiskirchen R. HeLa cells cross-contaminated nasopharyngeal carcinoma cell lines: Still a common problem. In: Br J Cancer, 2024, in press.

* Makowska A, Weiskirchen R. Nasopharyngeal carcinoma cell lines: Reliable alternatives to primary nasopharyngeal cells? In: Cells, 2024, 13:559.

* Nair DG, Weiskirchen R. Recent advances in liver tissue engineering as an alternative and complementary approach for liver transplantation. In: Curr Issues Mol Biol, 2024, 46, S. 262-278.

* Schröder SK, Krizanac M, Kim HK, Kessel JC, Weiskirchen R. Ovaries of estrogen receptor 1-deficient mice show iron overload and signs of aging. In: Front Endocrinol, 2024, 15:1325386.

* van Helden J, Eidens M, Fuhrländer J, Weiskirchen R, Øgreid D. DNA signature and occult blood in stool led to diagnosis of an early-onset metastatic rectal cancer in a young pregnant woman. In: SSRN, 461403 (Preprint). doi: 10.2139/ssrn.4671403

* Weiskirchen W, Kankel S, Liehr T. Short tandem repeat profile for authentication of immortal murine cancer cell line MH-22A. In: Cell Tissue Biol, 2024, in press.

* Yadav P, Singh SK, Rajput S, Allawadhi P, Khurana A, Weiskirchen R, Navik U. Therapeutic potential of stem cells in regeneration of liver in chronic liver diseases: Current perspectives and future challenges. In: Pharmacol Ther, 2024, 253, 1085673.

* Barer L, Schröder SK, Weiskirchen R, Bacharach E, Ehrlich M. Lipocalin 2 regulates the expression of interferon-stimulated genes and the susceptibility of prostate cancer cells to oncolytic virus infection. In: Eur J Cell Biol, 2023, 102:151328.

* Borkham-Kamphorst E, Meurer SK, Weiskirchen R. Expression and biological function of the cellular communication network factor 5 (CCN5) in primary liver cells. In: J Cell Commun Signal, 2023. 17, S. 307-320.

* Capellmann S, Sonntag R, Schüler H, Meurer SK, Gan L, Kauffmann M, Horn K, Königs-Werner H, Weiskirchen R, Liedtke C, Huber M. Transformation of primary murine peritoneal mast cells by constitutive KIT activation as a result of lost Cdkn2a/Arf expression. In: bioRxiv 2023, 2023.01.24.525344. doi: 10.1101/2023.01.24.525344.

* Capellmann S, Sonntag R, Schüler H, Meurer SK, Gan L, Kauffmann M, Horn K, Königs-Werner H, Weiskirchen R, Liedtke C, Huber M. Transformation of primary murine peritoneal mast cells by chronic KIT activation is accompanied by loss of Cdkn2a/Arf expression. In: Front Immunol, 2023, 14:1154416.

* Chaudhary R, Goodman LS, Wang S, Asimakopoulos A, Weiskirchen R, Dooley S, Ehrlich M, Henis YI. Cholesterol modulates type I-type II TGF-b receptor complexes and alters the balance between Smad and Akt signaling in hepatocytes. In: Research Square (Preprint), 2023, doi: 10.21203/rs.3.rs-2678204/v1.

* Chen G, Weiskirchen S, Weiskirchen R. Vitamin A: Too good to be bad? In: Front Pharmacol, 2023, 14:1186336.

* Friedman SL, Weiskirchen R. Working with immortalized hepatic stellate cell lines. In: Methods Mol Med, 2023, 2669, S. 129-162.

* Gäberlein K, Schröder SK, Nanda I, Steinlein C, Haaf T, Buhl EM, Sauvant P, Sapin V, Abergel A, Weiskirchen R. Genetic characterization of rat hepatic stellate cell line PAV-1. In: Cells, 2023, 12:1603.

* Hohlstein P, Brozat JF, Schuler J, Jhaisha SA, Pollmanns MR, Bündgens L, Wirtz TH, Yagmur E, Hamesch K, Weiskirchen R, Tacke F, Trautwein C, Koch A. Secreted Frizzled Related Protein 5 (SFRP5) serum levels are decreased in critical illness and sepsis and are associated with short-term mortality. In: Biomedicines, 2023, 11:313.

* Hu S, Li Y, Zhou J, Xu K, Pang Y, Weiskirchen R, Ocker M, Ouyang F. Identification of acetylshikonin as a novel tubulin polymerization inhibitor with antitumor activity in human hepatocellular carcinoma cells. In: J Gastrointest Oncol, 2023, 6, 2574-2586.

* Kalmer M, Grasshoff M, Maie T, Pannen K, Toledo MAS, Vieri M, Olschok K, Lemanzyk R, Lazarevic J, Baumeister J, Maurer A, Schifflers J, Kicheldorf K, Schemionek M, Brümmendorf TH, Weiskirchen R, Zenke M, Chatain N, Costa IG, Koschmieder S. Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alpha vera. In: Research Square, 2023, doi: 10.21203/rs.3.rs-3490651/v1.

* Kaushal A, Khurana I, Yadav P, Allawadhi P, Banothu AK, Neeradi D, Thalugula S, Barani PJ, Naik RR, Navik U, Bharani KK, Khurana A. Advances in therapeutic applications of silver nanoparticles. In: Chem Biol Interact, 2023;382:110590.

* Keshavarz-Fathi M, Yazdanpanah N, Kolahchi S, Ziaei H, Darmstadt GL, Dorigo T, Dochy F, Levin L, Thongboonkerd V, Ogino S, Qaim M, Chen W-H, Perc M, Tremblay MS, Olusanya BO, Rao IM, Hatziargyriou N, Moradi-Lakeh M, Bella F, Rosival L, Gandomi AH, Sorooshian A, Gupta M, Rovelli C, Gal C, Lozano AM, Weaver C, Tanzer M, Poggi A, Sepanlou SG, Weiskirchen R, Glover V, Režek Jambrak A, Torres PJ, Capanoglu E, Barba FJ, Ernest CKJ, Sigman M, Pluchino S, Gharehpetian GB, Sherwood S, Fereshtehnejad S-M, Yang M-H, Thomas S, Cai W, Comini E, Scolding NJ, Myles PS, Nieto JJ, Perry G, Sedikides C, Rezaei N; USERN Advisory Board Members. Universal Research UR-Index: An inclusive metric to quantify scientific research output. In: J Acad Librariansh, 2023, 49(3):102714.

* Kessel JC, Weiskirchen R, Schröder SK. Expression analysis of Lipocalin 2 (LCN2) in reproductive and non-reproductive tissues of Esr1-deficient mice. In: Int J Mol Sci, 2023, 24:9280.

* Krizanac M, Mass Sanchez PB, Schröder SK, Weiskirchen R, Asimakopoulos A. Lipid-independent regulation of PLIN5 via IL-6 through the JAK/STAT3 axis in Hep3B cells. In: Int J Mol Sci, 2023, 24:7219.

* Lurje I, Gaisa N, Weiskirchen R, Tacke F. Mechanisms of organ fibrosis: emerging diagnostic and therapeutic strategies. In: Mol Aspects Med, 2023, 92:101191.

* Melnik BC, Weiskirchen R. Exosomen der Muttermilch: Lebenswirksame Programmierung. In: DHZ, 2023, 75(11): 70-75.

* Melnik BC, John SM, Carreras-Bastos P, Cordain L, Leitzmann C, Weiskirchen R, Schmitz G. The role of cow’s milk consumption in breast cancer initiation and progression. In: Curr Nutr Rep, 2023, 12, S. 122-140.

* Melnik BC, Stadler R, Weiskirchen R, Leitzmann C, Schmitz G. Potential pathogenic impact of cow´s milk consumption and milk-derived exosomal microRNAs in diffuse large B-cell lymphoma. In: Int J Mol Sci, 2023, 24:6102.

* Meurer SK, Weiskirchen S, Tag CG, Weiskirchen R. Isolation and culture of primary murine hepatic stellate cells: An update. In: Methods Mol Med, 2023, 2669, S. 1-32.

* Müller N, Scheld M, Voelz C, Gasterich N, Zhao W, Behrens V, Weiskirchen R, Baazm M, Clarner T, Beyer C, Sanadgol N, Zendedel A. Lipocalin-2 deficiency diminishes canonical NLRP3 inflammasome formation and IL-1β production in the subacute phase of spinal cord injury. In: Int J Mol Sci, 2023, 24:8689.

* Nevzorova YA, Weiskirchen R, Liedtke C. Mouse models for hepatic stellate cell activation and liver fibrosis initiation. In: Methods Mol Med, 2023, 2669, S. 177-192.

* Otto J, Verwaayen A, Penners C, Hundertmark J, Lin C, Kallen C, Paffen D, Otto T, Berger H, Tacke F, Weiskirchen R, Nevzorova YA, Bartneck M, Trautwein C, Sonntag R, Liedtke C. Expression of Cyclin E1 in hepatic stellate cells is critical for the induction and progression of liver fibrosis and hepatocellular carcinoma in mice. In: Cell Death Differ, 2023, 14:549.

* Penning LC, Berenguer M, Czlonkowska A, Double KL, Dusek P, Espinós C, Lutsenko S, Medici V, Papenthin W, Stremmel W, Willemse J, Weiskirchen R. A century of progress onWilson disease and the enduring challenges of genetics, diagnosis, and treatment. In: Biomedicines, 2023, 11:420.

* Schröder SK, Tag CG, Weiskirchen S, Weiskirchen R. Phalloidin staining for F-actin in hepatic stellate cells. In: Methods Mol Med, 2023, 2669, S. 55-66.

* Schröder SK, Gasterich N, Weiskirchen S, Weiskirchen R. Lipocalin 2 receptors: Facts, fictions, and myths. In: Front Immunol, 2023, 14:1229885.

* Stremmel W, Weiskirchen R. Morbus Wilson: Mehr als eine einfache Kupferüberladung des Organismus? Ein narrativer Rückblick. In: Morbus Wilson Nachrichten, 2023, S. 28-35.

* Tezcan O, Elshafei AS, Benderski K, Rama E, Wagner M, Moeckel D, Pola R, Pechar M, Etrych T, von Stillfried S, Kiessling F, Weiskirchen R, Meurer SK, Lammers T. Effect of cellular and microenvironmental multidrug resistance on tumor-targeted drug delivery in triple-negative breast cancer. In: J Control Release, 2023, 354, S. 784-793

* Verma A, Yadav P, Rajput S, Verma S, Arora S, Kumar R, Bhatti JS, Khurana A, Navik U. ALK and ERBB2 protein inhibition is involved in the prevention of lung cancer development by vincamine. In: Anticancer Agents Med Chem, 2023, 23(13), S. 1587-1595.

* Vucur M, Ghallab A, Schneider AT, Adili A, Cheng M, Castoldi M, Singer MT, Büttner V, Keysberg LS, Küsgens L, Kohlhepp M, Görg B, Gallage S, Barragan Avila JE, Unger K, Kordes C, Leblond AL, Albrecht W, Loosen SH, Lohr C, Jördens MS, Babler A, Hayat S, Schumacher D, Koenen MT, Govaere O, Boekschoten MV, Jörs S, Villacorta-Martin C, Mazzaferro V, Llovet JM, Weiskirchen R, Kather JN, Starlinger P, Trauner M, Luedde M, Heij LR, Neumann UP, Keitel V, Bode JG, Schneider RK, Tacke F, Levkau B, Lammers T, Fluegen G, Alexandrov T, Collins AL, Nelson G, Oakley F, Mann DA, Roderburg C, Longerich T, Weber A, Villanueva A, Samson AL, Murphy JM, Kramann R, Geisler F, Costa IG, Hengstler JG, Heikenwalder M, Luedde T. Sublethal necroptosis signaling promotes inflammation and liver cancer. In: Immunity, 2023, 56, S. 1578-1595.

* Wang S, Link F, Han M, Chaudhary R, Asimakopoulos A, Liebe R, Yao Y, Hammad S, Dropmann A, Krizanac M, Rubie C, Feiner LK, Glanemann M, Ebert MPA, Weiskirchen R, Henis Y, Ehrlich M, Dooley S. The interplay ofTGF-β1 and cholesterol orchestrating hepatocyte cell fate, EMT, and signals for HSC activation. In: Cell Mol Gastroenterol Hepatol, 2023, 17, S. 567-587.

* Wang S, Link F, Han M, Liebe R, YaoY, Hammad S, Dropmann A, Chaudhary R, Asimakopoulos A, Krizanac M, Weiskirchen R, Henis YI, Ehrlich M, Ebert MPA, Dooley S. TGF-b1 inhibits cholesterol metabolism in hepatocytes to facilitate cell death, EMT and signals for HSC activation (Preprint). In: bioRxiv, 2023, doi: 10.1101/2023.08.14.552900.

* Weiskirchen R. Research reporting guidelines for cell lines: More than just a recommendation (Editorial commentary). In: Ann Transl Med, 2023, 11(12): 421.

* Weiskirchen R. Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution. In: Hepatology, 2023,77:E66.

* Weiskirchen R. Established hepatic stellate cell lines in hepatology research. In: Fibrosis, 2023, 1:10003.

* Weiskirchen R. CCNs and other extracellular matrix proteins: An introduction to the Special Issue (Guest Editorial). J Cell Commun Signal, 2023, 17, S. 229-232.

* Weiskirchen R. Targeting copper to combat macrophage-driven inflammation: A potential advanced therapeutic strategy. In: Signal Transduct Target Ther, 2023, 8(1):339. doi: 10.1038/s41392-023-01592-4

* Weiskirchen R, Schröder SK, Weiskirchen S, Buhl ME, Melnik B. Isolation of bovine and human milk extracellular vesicles. In: Biomedicines, 2023, 11(10):2715.

* Weiskirchen R, Friedman SL. Book Review: Weiskirchen, R.; Friedman, S.L. Hepatic Stellate Cells: Methods and Protocols, 1st Edition; Weiskirchen, R., Friedman, S.L., Eds.; Methods in Molecular Biology 2669; Humana Press: New York, 2023; ISBN 978-1-07-163206-2; eISBN: 978-1-0716-3207-9. In: Livers, 2023, 3, S. 293-299.

* Weiskirchen R, Friedman SL. Preface. In: Hepatic stellate cells: Methods and Protocols (Eds. R. Weiskirchen, S. L. Friedman). Methods in Molecular Biology. Humana Press, Springer 2023, pp. v, xiii. ISBN 978-1-07-163206-2

* Weiskirchen R, Sauerbruch T. Special issue “Liver fibrosis: Mechanisms, targets, assessment and treatment” (Editorial). In: Livers, 2023, S. 322-324.

* Weiskirchen S, Schröder SK, Buhl EM, Weiskirchen R. A beginner’s guide to cell culture: Practical advice for preventing needless problems. In: Cells, 2023, 12:682.

* Weiskirchen S, Schröder SK, Buhl EM, Weiskirchen. Cell culture. Encyclopedia. Available online: https://encyclopedia.pub/entry/41838.

* Weiskirchen R, Sorrentino D, Stremmel WR. Inflammation and fibrosis in the gastrointestinal tract and liver: Mechanisms and targets. Lausanne: Frontiers Media SA, 2023. doi: 10.3389/978-2-88971-626-5; ISSN 1664-8714; ISBN 978-2-88971-626-5.

* Weiskirchen R, Weiskirchen S, Tag CG, Meurer SK. Induction of obstructive cholestasis in mice. In: Methods Mol Med, 2023, 2669, S.163-175.

* Yazdanpanah N, Dochy F, Darmstadt GL, Peters GJ, Tsitlakidis A, Aifantis EC, Cerda A, Comini E, Brand S, Gupta M, Cheson BD, Thomas S, Tanzer M, Weiskirchen R, Bella F, Fereshtehnejad S-M, Nikita K, Ali I, Kato K, Poggi A, Jon ECK, Rao IM, Tao X, He J-H, Rao LJM, Leemans A, Pomponio A, Hernandez AM, Ahmadieh H, Sahraian MA, Kelishadi R, Thongboonkerd V, Bahinipati S, Toi M, von Herrath M, Sellke F, Sherwood S, Perry G, Nieto JJ, Gupta S, Dorigo T, Mobasher B, Ochs HD, Rezaei N; USERN Advisory Board Members. Cancer: A complex problem requires interdisciplinary research. In: Interdisciplinary Cancer Research (Ed. Nima Rezaei), Springer, Cham., 2023, in press. doi: 10.1007/16833_2022_116, S. 1-45.

* Yazdanpanah N, Sedikides C, Ochs HD, Camargo Jr CA, Darmstadt GL, Cerda A, Cauda V, Peters GJ, Sellke F, Wong ND, Comini E, Ruiz Jimeno A, Glover V, Hatziargyriou N, Vincenot CE, Bordas SPA, Rao IM, Abolhassani H, Gharehpetian GB, Weiskirchen R, Gupta M, Chandel SS, Olusanya BO, Cheson B, Pomponio A, Tanzer M, Myles PS, Ma W-X, Bella F, Ghavami S, Moein Moghimi S, Pratico D, Martinez Hernandez A, Martinez Urbistondo M, Martinez Urbistondo D, Fereshtehnejad SM, Ali I, Kimura S, Hayes W, Cai W, Ernest CKJ, Thomas S, Rahimi K, Sorooshian A, Schreiber M, Kato K, Luong JHT, Pluchino S, van den Bergh J, Lozano AM, Seymour J, Kosik KS, Hofmann SG, McIntyre Rs, Perc M, Leemans A, Klein RS, Ogino S, Wlezien C, Perry G, Gupta S, Nieto JJ, Levin L, Klionsky DJ, Mobasher B, Dorigo T, Rezaei T, USERN Advisory Board. Global challenges coming after a global challenge: Lessons learned from the COVID-19 pandemic. In: Adv Exp Med Biol, 2023, in press.

* Zhang K, Cheng Y, Peng Y, Jiang F, Zhang C, Ng CSH, Rosell R, Efird JT, Lai A, Nappi F, Weiskirchen R, Uchida S, Chua MT, D’Ambrosi R.Scope highlights of Annals of Translational Medicine based on a review of the history, definition and scope of translational medicine (Editorial). In: Ann Transl Med, 2023, 11(11):381.

* Allawadhi P, Singh V, Govindaraj K, Khurana I, Sarode LP, Navik U, Banothu AK, Weiskirchen R, Bharani KK, Khurana A. Biomedical applications of polysaccharide nanoparticles for chronic inflammatory disorders: Focus on rheumatoid arthritis, diabetes and organ fibrosis. In: Carbohydr Polym, 2022, 281, 118923.

* Assar MAM, Hüffel M, Afify M, Weiskirchen R, Eisert A, Tolba RH, Steitz J. Effects of asparaginases and L-carnitine on Western-diet-induced hepatosteatosis in mice. In: F1000Res, 2022, 11:128.

* Bertges M, Ketikidou A, Weiskirchen R, van Helden J, Boehnke R, Hess C. Manipulation of THC hair concentrations by commercially available products. In: Metabolites, 2022, 12:900.

* Bertges M, Weiskirchen R. Quantification of chloride in sweat by using ion chromatography instead of chloridometer. In: SN Appl Sci, 2022, 4:273.

* Bertges M, Weiskirchen R, van Helden J. Analytical detection of prenatal drug exposure in early childhood in prenatal and postnatal matrices. In: Rom J Leg Med, 2022, 30, S. 46-52.

* Czubala MA, Eilles E, Staubi A, Ipseiz N, Vogt M, Zieglowski L, Ernst L, Tolba RH, Taylor PR, Weiskirchen R. 3R Blackboard: A platform for animal and organ sharing. In: Lab Anim, 2022, 56, S. 292-296.

* Gasterich N, Bohn A, Sesterhenn A, Nebelo F, Fein L, Kaddatz H, Kant S, Kipp M, Weiskirchen R, Zendedel A, Beyer C, Clarner T. Lipocalin 2 attenuates oligodendrocyte loss and immune cell infiltration in mouse models for multiple sclerosis. (Cover story) In: Glia, 2022, 70, S. 2188-2206.

* Heinrich L, Booijink R, Khurana A, Weiskirchen R, Bansal R. Lipoxygenases in chronic liver diseases: Current insights and future perspectives. In: Trends Pharmacol Sci, 2022, 43, S. 188-205.

* Khurana A, Navik U, Allawadhi P, Yadav P, Weiskirchen R. Spotlight on liver macrophages for halting liver disease progression and injury. In: Expert Opin Ther Targets, 2022, 26, S. 707-719.

* Khurana A, Sayed N, Singh V, Khurana I, Allawadhi P, Rawat PS, Navik U, Pasumarthi SK, Bharani KK, Weiskirchen R. A comprehensive overview of CRISPR/Cas 9 technology and application thereof in drug discovery. In: J Cell Biochem, 2022, 123, S. 1674-1698.

* Khurana A, Weiskirchen R, Singh V, Navik U, Allawadhi P, Bharani KK. Apoptosis-associated protein domains. E Scholarly Community Encyclopedia. Available online at: https://encyclopedia.pub/entry/22358.

* Liedtke C, Nevzorova YA, Luedde T, Zimmermann H, Kroy D, Strnad P, Berres ML, Bernhagen J, Tacke F, Nattermann J, Spengler U, Sauerbruch T, Wree A, Abdullah Z, Tolba RH, Trebicka J, Lammers T, Trautwein C, Weiskirchen R. Liver fibrosis - From mechanisms of injury to modulation of disease. In: Front Med, 2022, 8:814496.

* Manzhalii EG, Falalyeyeva TM, Moyseyenko VO, Weiskirchen R, Stremmel W. Elevation of autoantibodies to cerebral proteins in hepatic encephalopathy: Another pathogenic factor? In: Dig Dis, 2022, 40, S. 232-238.

* Melnik BC, John SM, Weiskirchen R, Schmitz G. The endocrine and epigenetic impact of persistent cow milk consumption on prostate cancerogenesis. In: J Transl Genet Genom, 2022, 6, S. 1-45.

* Melnik BC, Weiskirchen R, Schmitz G. Milk exosomal microRNAs: Friend of foe? In: ExRNA, 2022, 4:22.

* Melnik BC, Weiskirchen R, Stremmel W, John SM, Schmitz G. Narrative review of bovine milk exosomes as a potential therapeutic option for hepatic fibrosis. In: Dig Med Res, 2022, 5:14.

* Melnik BC, Weiskirchen R, Stremmel W, Schmitz G. Letter to the Editor regarding “Dietary bovine milk miRNAs transported in extracellular vesicles are partially stable during GI digestion, are bioavailable and reach target tissues but need a minimum dose to impact on gene expression”. In: Eur J Nutr, 2022, 61, S. 1695-1696.

* Meurer SK, Brenner DA, Weiskirchen R. Multiplex short tandem repeat profiling of immortalized hepatic stellate cell line Col-GFP HSC. In: PLoS ONE, 2022, 17(9):e0274219.

* Moeller MJ, Kramann R, Lammers T, Hoppe B, Latz E, Ludwig-Portugall I, Boor P, Floege J, Kurts C, Weiskirchen R, Ostendorf T. New aspects of kidney fibrosis - From mechanisms of injury to modulation of disease. In: Front Med, 2022, 8:814497.

* Nanda I, Steinlein C, Haaf T, Buhl EM, Grimm DG, Friedman SL, Meurer SK, Schröder SK, Weiskirchen R. Genetic characterization of rat hepatic stellate cell line HSC-T6 for in vitro cell line authentication. In: Cells 2022, 11:1783.

* Nanda I, Schröder SK, Steinlein C, Haaf T, Buhl EM, Grimm  DG, Weiskirchen R. Rat hepatic stellate cell line CFSC-2G: Genetic markers and short tandem repeat profile useful for cell line authentication. In: Cells, 2022, 11:2900.

* Narasimhan H, Ferraro F, Bleilevens A, Weiskirchen R, Stickeler E, Maurer J. Tumor necrosis factor-α (TNFα) stimulate triple negative breast cancer stem cells to promote intratumoral invasion and neovasculogenesis in the liver of a xenograft model. In: Biology, 2022, 11:1481.

* Pasumarthi SK, Khurana A, Weiskirchen R. Gene therapy: An emerging therapeutic approach. In: Pharma Focus Asia, 2022, 49, S.54-56.

* Poggel C, Adams T, Janzen R, Hofmann A, Hardt O, Roeb E, Schröder SK, Tag CG, Roderfeld M, Weiskirchen R. Isolation of hepatocytes from liver tissue by a novel, semi-automated perfusion technology. In: Biomedicines, 2022, 10:2198.

* Sayed N, Allawadhi P, Khurana A, Singh V, Navik U, Khurana I, Weiskirchen R, Banothu AK, Bharani KK. Gene therapy: Comprehensive overview and therapeutic applications. In: Life Sciences, 2022, 294:120375.

* Schneiders S, Schifflers MC, Weiskirchen S, Weiskirchen R. Quiz Entzündung (Teil 2). In: MTA Dialog, 2022, 23(1), S. 44-45.

* Schneiders S, Schifflers MC, Weiskirchen S, Weiskirchen R. Quiz Entzündung (Teil 3). In: MTA Dialog, 2022, 23(3), S. 210-211.

* Schneiders S, Schifflers MC, Weiskirchen S, Weiskirchen R. Quiz Entzündung (Teil 4). In: MTA Dialog, 2022, 23(4), S.295.

* Schröder SK, Tag CG, Kessel JC, Antonson P, Weiskirchen R. Immunohistochemical detection of estrogen receptor-beta (ERβ) with PPZ0506 antibody in murine tissue: From pitfalls to optimization. In: Biomedicines, 2022;10:3100.

* Schröder SK, Pinoé-Schmidt M, Weiskirchen R. Lipocalin-2 (LCN2) deficiency diminishes metastatic characteristics of human PC-3 prostate cancer cells. In: Cells, 2022, 11:260.

* Schröder SK, Schüler HM, Petersen KV, Tesauro C, Knudsen BR, Pedersen FS, Krus F, Buhl EM, Roeb E, Roderfeld M, Borojevic R, Almeida JL, Weiskirchen R. Genetic and molecular characterization of the immortalized murine hepatic stellate cell line GRX. In: Cells 2022, 11:1504.

* Singh V, Khurana A, Navik U, Allawadhi P, Bharani KK, Weiskirchen R. Apoptosis and pharmacological therapies for targeting thereof for cancer therapeutics. In: Sci, 2022, 4:15.

* Singh V, Renushe AP, Allawadhi P, Pasumarthi SK, Khurana I, Weiskirchen R, Neeradi D, Banothu AK, Bharani KK, Khurana A. Pharmacological modeling of gastrointestinal disorders in zebrafish for drug discovery and development. In: Zebrafish model for biomedical research. Prasan R. Bhandari, Kala K. Bharini, Amit Khurana), Eds. Springer Verlag, Singapore, 2022. Hardcover ISBN: 978-981-16-5216-5, eBook ISBN: 978-981-16-5217-2 doi: 10.1007/978-981-16-5217-2. pp 421-447.

* Stremmel W, Fricker G, Weiskirchen R. Saturated phosphatidylcholine as dietary additive for colonic mucus: an open label prospective clinical observation trial. In: AME Med J, 2022, 7:10.

* Stremmel W, Vural H, Evliyaoglu O, Weiskirchen R. Wirksamkeit von darmlöslichem Lecithin (Phosphatidylcholin) zur Behandlung der Colitis ulcerosa: Eine Meta-Analyse. In: MMW Fortschritte der Medizin, 2022, 164(S7), S. 3-11.

* Stremmel W, Weiskirchen R. Therapeutische Strategien bei Morbus Wilson: Pathophysiologie und Wirkungsweise. In: Morbus Wilson Nachrichten 2022, 2022, S. 25-33 (Coverstory).

* Stremmel W, Weiskirchen R. Wilson disease: More complex than just simply a copper overload condition. In: AME Med J, 2022, 7:26.

* Swoboda J, Mittelsdorf P, Chen Y, Weiskirchen R, Stallhofer J, Schüle S, Gassler N. Intestinal Wnt in the transition from physiology to oncology. In: World J Gastrointest Oncol, 2022, 13(3), S. 168-185.

* Weiskirchen R. Cell line misidentification: Does Crocetin protect against TGF-β-induced liver damage? (Commentary) In: Front Public Health, 2022, 10:1002484.

* Weiskirchen R. Autophagy in parenchymal and non-parenchymal liver cells. E Scholarly Community Encyclopedia. Available online at: https://encyclopedia.pub/19512.

* Weiskirchen R. Cell therapy in liver fibrosis. E Scholarly Community Encyclopedia. Available online at: https://encyclopedia.pub/entry/18425.

* Weiskirchen R. Established liver cell lines: Are you sure to have the right ones? (Cover story) In: Livers, 2022, 2(3), S. 171-177.

* Weiskirchen R. Novel therapeutic targets in liver pathology: From basic science to clinical translation (Editorial). In: J Cell Biochem, 2022, 123, S. 1529-1531.

* Weiskirchen R, Liao A, Gao LM. Interview with Prof. Ralf Weiskirchen: challenges and opportunities in gastroenterology and hepatology. In: Dig Med Res, 2022, 5:50.

* Weiskirchen R. Interpretation of data needs attention. Comment on: Cytotoxic effects of Lavandula angustifolia seed extracts on the viability of Huh-7 and Chang liver cells by G. M. Alshammari (PLoS ONE 2022;17(4):e0267499). Available online at: https://journals.plos.org/plosone/article/comments?id=10.1371/journal.pone.0267499.

* Weiskirchen R. Magnetic-assisted treatment of liver fibrosis. E Scholarly Community Encyclopedia. Available online at: https://encyclopedia.pub/entry/18713.

* Weiskirchen R. Special Issue on “Cellular and molecular mechanisms underlying the pathogenesis of hepatic fibrosis II” (Editorial). In: Cells, 2022, 11:2403.

* Weiskirchen R. The Beatles in life sciences: Facts and fictions. In: Biochem Mol Biol Educ, 2022, 50, S. 334-344.

* Weiskirchen R, Izzo AA. Editorial: Insights in Gastrointestinal and Hepatic Pharmacology: 2021. In: Frontiers in Pharmacol, 2022, 13:890212.

* Weiskirchen R, Singh V, Khurana A, Navik U, Allawadhi P, Bharani KK. Process of apoptosis. E Scholarly Community Encyclopedia. Available online at: https://encyclopedia.pub/entry/22317.

* Weiskirchen R, Tacke F. Pathophysiologie: Immunologie. In: Nichtalkoholische Fettleber. (Eds. Andreas Geier, Ali Canbay & Frank Lammert). Springer, Berlin, Heidelberg. https://www.springer.com/de/book/9783662624838; doi: 10.1007/978-3-662-62484-5_7; ISBN 978-3-662-62483-8. pp. 63-73.

* Yadav P, Khurana A, Bhatti JS, Weiskirchen R, Navika U. Glucagon-like peptide 1 and fibroblast growth factor in non-alcoholic steatohepatitis: An experimental to clinical perspective. In: Pharmacol Res, 2022, 184:106426.

* Yadav P, Sarode LP, Gaddam RR, Kumar P, Bhatti JS, Khurana A, Navik U. Zebrafish as an emerging tool for drug discovery and development for thyroid diseases. In: Fish Shellfish Immunol, 2022, 130, S. 53-60.

* Yagmur E, Jhaisha SA, Buendgens L, Sapundzhieva N, Brozat JF, Hohlstein P, Pollmanns MR, Koek GH, Weiskirchen R, Trautwein C, Tacke F, Wirtz TH, Koch A. Clusterin plasma concentrations are decreased in sepsis and inversely correlated with established markers of inflammation. In: Diagnostics, 2022, 12:3010.

* Acharya P, Chouhan K, Weiskirchen S, Weiskirchen R. Cellular mechanisms of liver fibrosis. In: Front Pharmacol, 2021, 12:671640.

* Bartneck M, Koppe C, Fech V, Warzecha KT, Kohlhepp M, Huss S, Weiskirchen R, Trautwein C, Luedde T, Tacke F. Roles of CCR2 and CCR5 for hepatic macrophage polarization in mice with liver parenchymal cell-specific NEMO deletion. In: Cell Mol Gastroenterol Hepatol, 2021, 11, S. 327-347.

* Bertges M, van Helden J, Weiskirchen R. Quantification of short chain fatty acids (acetate, butyrate, propionate) in human blood with ion exclusion chromatography. In: Pract Lab Med, 2021, 26, e00244.

* Borkham-Kamphorst E, Haas U, Pinoé-Schmidt M, Abdallah AT, Weiskirchen R. Chronic mineral oil administration increased hepatic inflammation in wild type mice compared to Lipocalin 2 null mice. In: Lab Invest, 2021, S. 1528-1539. 

* Brockhaus J, Craveiro RB, Azraq I, Niederau C, Schröder SK, Weiskirchen R, Jankowski J, Wolf M. In-vitro compression-model for orthodontic tooth movement modulates human periodontal ligament fibroblast proliferation, apoptosis and cell cycle. In: Biomedicines, 2021, 11:932.

* Cierpka R, Weiskirchen R, Asimakopoulos A. Perilipin 5 ameliorates hepatic stellate cell activation via SMAD2/3 and SNAIL signaling pathways and suppresses STAT3 activation. In: Cells, 2021, 10:2184.

* Drescher HK, Weiskirchen S, Weiskirchen R. Flow cytometry: A blessing and a curse. In: Biomedicines, 2021, 9:1613.

* Gasterich N, Wetz S, Tillmann S, Fein L, Seifert A, Slowik A, Weiskirchen R, Zendedel A, Ludwig A, Koschmieder S, Beyer C, Clarner T. Inflammatory responses of astrocytes are independent from lipocalin 2. In: J Mol Neurosci, 2021, 71, S. 933-942.

* Gehrke SG, Förderer C, Weiskirchen R, Stremmel W. SARS-CoV-2 airborne surveillance using non-powered cold traps. In: Environ Monit Assess, 2022, 193:778.

* Heinrichs D, Brandt EF, Fischer P, Köhncke J, Wirtz TH, Guldiken N, Djudjaj S, Boor P, Kroy D, Weiskirchen R, Bucala R, Wasmuth HE, Strnad P, Trautwein C, Bernhagen J, Berres ML. Unexpected pro-fibrotic effect of MIF in non-alcoholic steatohepatitis is linked to a shift in NKT cell populations. In: Cells, 2021, 10:252.

* Kabiri P, Weiskirchen R, van Helden J. The biotin interference within interference suppressed immunoassays. In: J Clin Lab Anal, 2021, 9:e23940.

* Khurana A, Allawadhi P, Khurana I, Allwadhi S, Banothu AK, Joshi K, Chhabra D, Weiskirchen R, Bharani KK. Role of nanotechnology behind the success of mRNA vaccines for COVID-19. In: Nano Today, 38, 101142.

* Khurana A, Sayed N, Allawadhi P, Weiskirchen R. It’s all about the spaces between cells: role of extracellular matrix in liver fibrosis. In: Ann Transl Med, 2021, 9(8):728.

* Kim P, Zhang CC, Thoröe-Boveleth S, Buhl EM, Weiskirchen S, Stremmel W, Merle U,  Weiskirchen R. Analyzing the therapeutic efficacy of bis-choline-tetrathiomolybdate in the Atp7b^-/- copper overload mouse model. In: Biomedicines, 2021, 9:1861.

* Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, …….., Weiskirchen R, Stallings CL, Tong CK. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). In: Autophagy, 2021, 17, S. 1-382.

* Klüber P, Meurer SK, Lambertz J, Schwarz R, Zechel-Gran S, Braunschweig T, Hurka S, Domann E, Weiskirchen R. Depletion of Lipocalin 2 (LCN2) in mice leads to dysbiosis and persistent colonization with segmented filamentous bacteria. In: Int J Mol Sci, 2021, 22:13156.

* Krizanac M, Maas Sanchez PB, Weiskirchen R, Asimakopoulos AA. Scoping review on Lipocalin-2 and its role in non-alcoholic steatohepatitis and hepatocellular carcinoma. In: Int J Mol Sci, 2021, 22:2865.

* Kurt B, Buendgens L, Wirtz TH, Loosen SH, Schulze-Hagen M, Truhn D, Brozat JF, Jhaisha SA, Hohlstein P, Koek G, Weiskirchen R, Trautwein C, Tacke F, Hamesch K, Koch A. Serum perilipin 2 (PLIN2) predicts multiple organ dysfunction in critically ill patients. In: Biomedicines, 2021, 9:1210.

* Mass Sanchez PB, Krizanac M, Weiskirchen R, Asimakopoulos A. Understanding the role of perilipin 5 in non-alcoholic fatty liver disease and its role in hepatocellular carcinoma: A review of novel insights. In: Int J Mol Sci, 2021, 22:5284.

* Melnik BC, Stremmel W, Weiskirchen R, John SM, Schmitz G. Exosome-derived microRNAs of human breast milk and their effects on infant health and development. In: Biomedicines 2021;11:851.

* Roeb E, Weiskirchen R. Fructose and non-alcoholic steatohepatitis. In: Front Pharmacol, 2021, 12:634344.

* Roemhild K, von Maltzahn F, Weiskirchen R, Knüchel R, von Stillfried S, Lammers T. Iron metabolism: Pathophysiology and Pharmacology. In: Trends Pharmacol Sci, 2021, 42, S. 640-656.

* Schneiders S, Schifflers MC, Weiskirchen S, Weiskirchen R. Digitale Lehre in Zeiten von Corona mal anders. In: MTA Dialog, 2021, 22(3), S.188-189.

* Schneiders S, Schifflers MC, Weiskirchen S, Weiskirchen R. Repetitorium: Blutzellquiz. In: MTA Dialog 2021, 22(6), S. 460.

* Schneiders S, Schifflers MC, Weiskirchen S, Weiskirchen R. Repetitorium: Blutzellquiz (Teil 2). In: MTA Dialog, 2021, 22(4), S. 298.

* Schneiders S, Schifflers MC, Weiskirchen S, Weiskirchen R. Repetitorium: Blutzellquiz (Teil 3). In: MTA Dialog, 2021, 22(5), S. 372-373.

* Schneiders S, Schifflers MC, Weiskirchen S, Weiskirchen R. Digitale Lehre in Zeiten von Corona mal anders……es geht weiter! In: MTA Dialog, 2021, 22(6), S. 462-463.

* Schneiders S, Schifflers MC, Weiskirchen S, Weiskirchen R. Repetitorium: Urinsedimentequiz (Teil 2). In: MTA Dialog, 2021, 22(7), S. 538-539.

* Schneiders S, Schifflers MC, Weiskirchen S, Weiskirchen R. Repetitorium: Urinsedimentequiz (Teil 3). In: MTA Dialog, 2021, 22(8), S. 606-607.

* Schneiders S, Schifflers MC, Weiskirchen S, Weiskirchen R. Repetitorium: Urinsedimentequiz (Teil 4). In: MTA Dialog, 2021, 22(10), S. 799.

* Schneiders S, Schifflers MC, Weiskirchen S, Weiskirchen R. Wenn der Körper brennt: Entzündungsdiagnostik. In: MTA Dialog, 2021, 22(11), S. 884-885.

* Singh V, Khurana A, Allawadhi P, Kumar Banothu A, Kumar Bharani K, Weiskirchen R. Emerging role of PD-1/PD-L1 inhibitors in chronic liver diseases. In: Front Pharmacol, 2021, 12:790963.

* Stein CM, Weiskirchen R, Damm F, Strzelecka PM. Single-cell methods: Overview, analysis and application in biomedical sciences. In: J Cell Biochem, 2021, 122, S. 1571-1578.

* Stremmel C, Stremmel W, Kadioglu O, Efferth T, Weiskirchen R. The bile acid phospholipid conjugate ursodeoxycholate lysophoshatidylethanolamide acts by binding to calcium independent membrane phospholipase A₂ type beta. In: AME Med J, 2021, 6:24.

* Stremmel W, Fricker G, Weiskirchen R. Saturated phosphatidylcholine as dietary nutrition for colonic mucus. In: AME Med J, 2021, in press.

* Stremmel W, Vural H, Evliyaoglu O, Weiskirchen R. Delayed-release phosphatidylcholine is effective for treatment of ulcerative colitis: A meta-analysis. In: Dig Diseases, 2021, 39, S. 508-515.

* Stremmel W, Longerich T, Liere R, Vacata V, van Helden J, Weiskirchen R. Wilson disease - the impact of hyperimmunity on disease activity: A case report. In: World J Clin Cases, 2021, 9, S. 1386-1393.

* Stremmel W, Longerich T, Liere R, Vacata V, van Helden J, Weiskirchen R. Morbus Wilson – Der Einfluss der Hyperimmunität auf die Krankheitsaktivität: Ein Fallbericht. In: Morbus Wilson Nachrichten, 2021, 21, S. 39-44.

* Stremmel W, Lukasova M, Weiskirchen R. The neglected biliary mucus and its phosphatidylcholine content: a putative player in pathogenesis of primary cholangitis – a narrative review article. In: Ann Transl Med, 2021, 9(8):738.

* Stremmel W, Weiskirchen R. Therapeutic strategies in Wilson disease: pathophysiology and mode of action. In: Ann Transl Med, 2021, 9(8):732.

* Stremmel W, Weiskirchen R. Therapeutische Strategien bei Morbus Wilson: Pathophysiologie und Wirkungsweise. In: Morbus Wilson Nachrichten, 2021, 12(21): S. 39-43.

* Tacke F, Weiskirchen R. Non-alcoholoic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention. In. Ann Transl Med, 2021, 9(8):729.

* Tillmann S, Olschok K, Schröder SK, Bütow M, Baumeister J, Kalmer M, Preußger V, Weinbergerova B, Kricheldorf BK, Mayer J, Kubesova B, Racil Z, Wessiepe M, Eschweiler J, Isfort S, Brümmendorf TH, Becker W, Schemionek M, Weiskirchen R, Koschmieder S, Chatain N. The unfolded protein response is a major driver of LCN2 expression in BCR-ABL- and JAK2V617F-positive MPN. In: Cancers, 2021, 13:4210.

* Vural H, Tamer MN, Weiskirchen R. Evaluation of arginine-nitric oxide pathway in patients with hyperthyroidism. In: Electron J Gen Med, 2021, 18(2): em278.

* Vural H, Armutcu F, Akyol O, Weiskirchen R. The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases. In: Clin Chim Acta, 2021, 523, S. 374-379.

Weiskirchen R. Endoglin. E Scholarly Community Encyclopedia. Available online at: https://encyclopedia.pub/entry/3642.

Weiskirchen R. Exosome-derived microRNAs of human milk. E Scholarly Community Encyclopedia. Available online at: https://encyclopedia.pub/entry/10946.

* Weiskirchen R. The pathogenesis of hepatic fibrosis: Basic facts and clinical challenges. In: Dig Med Res, 2021, 4:62.

* Weiskirchen R. Commentary: Re-regulation of hepatic stellate cell contraction and cirrhotic portal hypertension by Wnt/β-catenin signaling via interaction with Gli1. In: Br J Pharmacol, 2021, 178, S. 378-380.

* Weiskirchen R. Commentary on: Physalin B attenuates liver fibrosis via suppressing LAP2α-HDAC1 mediated deacetylation of GLI1 and hepatic stellate cell activation. (Preprint). In: Authorea 2021 doi: 10.22541/au.161910085.54630440/v1 Availble online: https://www.authorea.com/users/376590/articles/519112-commentary-on-physalin-b-attenuates-liver-fibrosis-via-suppressing-lap2%CE%B1-hdac1-mediated-deacetylation-of-gli1-and-hepatic-stellate-cell-activation

* Weiskirchen R. Physalin B attenuates liver fibrosis via suppressing LAP2α-HDAC1 mediated deacetylation of GLI1 and hepatic stellate cell activation. In: Br J Pharmacol, 2021, 178, S. 4045-4047.

* Weiskirchen R, Asimakopoulos A. Lipocalin-2. E Scholarly Community Encyclopedia. Available online at: encyclopedia.pub/entry/9187.

* Weiskirchen R, Penning LC. COMMD1, a multi-potent intracellular protein involved in copper homeostasis, protein trafficking, inflammation, and cancer. In: J Trace Elem Med Biol, 2021, 65:126712.

* Weiskirchen R. Intratumor heterogeneity, variability and plasticity: questioning the current concepts in classification and treatment of hepatocellular carcinoma (第四章 瘤内异质性、可变性和可塑性：对当前肝细胞癌分类及 治疗概念的质疑). In: 2021, Key leaders' opinion on precision medicine in hepatobiliary cancer (Chinese version). H. Zhao & R. Weiskirchen (Eds). AME Publishing Company. Hong Kong, Hangzhou, Guangzhou, China, S. 10-14.

* Weiskirchen R, Sorrentino D, Stremmel WR. Editorial: Inflammation and fibrosis in the gastrointestinal tract and liver: Mechanisms and targets. In: Front Pharmacol, 2021, 12:773228.

* Weiskirchen R, Stremmel W. Unresolved basic issues in Hepatology. In: Ann Transl Med, 2021, 9(8):725.

* Weiskirchen S, Weiskirchen R. The Cape gooseberry constituent Physalin B ameliorates nonalcoholic steatohepatitis and attenuates liver fibrosis. In: Livers, 2021, 1, S. 98-101.

* Wirtz TH, Loosen SH, Schulze-Hagen M, Weiskirchen R, Buendgens L, Abu Jhaisha S, Brozat JF, Puengel T, Vucur M, Paffenholz P, Kuhl C, Tacke F, Trautwein C, Luedde T, Roderburg C, Koch A. CT-based determination of excessive visceral adipose tissue is associated with an impaired survival in critically ill patients. In: PLoS One, 2021, 16(4):e0250321.

* Wirtz TH, Saal A, Bergmann I, Fischer P, Heinrichs D, Brandt EF, Koenen MT, Djudjaj S, Schneider KM, Boor P, Bucala R, Weiskirchen R, Bernhagen J, Trautwein C, Berres ML. Macrophage migration inhibitory factor exerts pro-proliferative and anti-apoptotic effects via CD74 in murine hepatocellular carcinoma. In: Br J Pharmacol, 2021, 178, S. 4452-4467.

* Zieglowski L, Kümmecke A, Ernst L, Palme R, Weiskirchen R, Talbot SR, Tolba RH. Assessing the severity of laparotomy and partial hepatectomy in male rats – A multimodal approach. In: PLoS One, 2021, 16(8):e0255175.

* Zieglowski L, Kümmecke A, Ernst L, Palme R, Weiskirchen R, Talbot SR, Tolba RH. Assessing the severity of laparotomy and partial hepatectomy in male rats – a multimodal approach. In: Zenodo 2021. doi: 10.5281/zenodo.3842977.

* Akyol O, Chowdhury I, Akyol HR, Tessier K, Vural H, Akyol S. Why are cardiovascular diseases more common among patients with severe mental illness? The potential involvement of electronegative low-density lipoprotein (LDL) L5. In: Med Hypotheses, 2020, 142:109821.

* Armutcu F, Akyol S, Vural H. Metabolic syndrome is an important cornerstone in the health-disease line and pathological organ interaction. In: J Cell Signal, 2020, 1(3):70-75.

* Asimakopoulou A, Engel KM, Gassler N, Bracht T, Sitek B, Buhl EM, Kalampoka S, Pinoé-Schmidt M, van Helden J, Schiller J, Weiskirchen R. Deletion of Perilipin 5 protects against hepatic injury in nonalcoholic fatty liver disease via missing inflammasome activation. In: Cells, 2020, 9:1346.

* Asimakopoulou A, Vucur M, Luedde T, Schneiders S, Kalampoka S, Weiss TS, Weiskirchen R. Perilipin 5 and Lipocalin 2 expression in hepatocellular carcinoma. In: Heidari A, editor. Prime Archives in Cancer Research. Hyderabad, India: Vide Leaf. 2020. pp. 1-32.

* Azzam M, El Safy S, Abdelgelil SA, Weiskirchen R, Asimakopoulou A, de Lorenzi F, Lammers T, Mansour S, Tammam S. Targeting activated hepatic stellate cells using collagen-binding chitosan nanoparticles for siRNA delivery to fibrotic livers. In: Pharmaceutics, 2020, 12:590.

* Bansal R, Madrekar P, Mohanty SK, Weiskirchen R (eds). Macrophages in liver disease, Lausanne, Frontiers Media SA. ISBN 978-2-88966-038-4; doi: 10.3389/978-2-88966-038-4

* Bansal R, Mandrekar P, Mohanty SK, Weiskirchen R. Editorial: Macrophages in Liver Disease. In: Front Immunol, 2020, 11:1754.

* Borkham-Kamphorst E, Haas U, van de Leur E, Trevanich A, Weiskirchen R. Chronic carbon tetrachloride applications induced hepatocyte apoptosis in Lipocalin 2 null mice through endoplasmic reticulum stress and unfolded protein response. In: Int J Mol Sci, 2020, 21:5230.

* Buendgens L, Yagmur E, Ginsberg A, Weiskirchen R, Wirtz T, Jhaisha SA, Eisert A, Luedde T, Trautwein C, Tacke F, Koch A. Midregional proadrenomedullin (MRproADM) serum levels in critically ill patients are associated with short-term and overall mortality during a two-year follow-up. In: Mediat Inflamm, 2020, 2020:7184803.

* Buhl EM, Djudjaj S, Klinkhammer BM, Ermert K, Puelles Rodriguez VG, He C, Borkham-Kamphorst E, Weiskirchen R, Denecke B, Olson LE, Floege J, Boor P. Dysregulated mesenchymal PDGFR-β drives kidney fibrosis. In: EMBO Mol Med, 2020, e11021.

* Buniatian GH, Weiskirchen R, Weiss TS, Schwinghammer U, Fritz M, Seferyan T, Proksch B, Glaser M, Lourhmati A, Buadze M, Borkham-Kamphorst E, Gaunitz F, Gleiter CH, Lang T, Schaeffler E, Tremmel R, Cynis H, FreyII WH, Gebhardt R, Friedman SL, Mikulits W, Schwab M, Danielyan L. Antifibrotic effects of amyloid-beta and its loss in cirrhotic liver. In: Cells, 2020, 9:452.

* Cremonese C, Schierwagen R, Uschner FE, Torres S, Tyc O, Ortiz C, Schulz M, Queck A, Kristiansen G, Bader M, Sauerbruch T, Weiskirchen R, Walther T, Trebicka J, Klein S. Short-term Western diet aggravates non-alcoholic fatty liver disease (NAFLD) with portal hypertension in TGR(mREN2)27 rats. In: Int J Mol Sci, 2020, 21:3308.

* Drescher H, Bartsch LM, Weiskichen S, Weiskirchen R. Intrahepatic T_H17/T_Reg cells in homeostasis and disease -it's all about balance. In: Front Pharmacol, 2020, 11:588436.

* Drescher HK, Schippers A, Rosenhain S, Gremse F, Bongiovanni L, de Bruin A, Eswaran S, Gallage SU, Pfister D, Szydlowska M, Heikenwalder M, Weiskirchen S, Wagner N, Trautwein C, Weiskirchen R, Kroy DC. L-Selectin/CD62L is a key driver of non-alcoholic steatohepatitis in mice and men. In: Cells, 2020, 9:1106.

* Drescher HK, Weiskirchen S, Weiskirchen R. Current status in testing for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). In: Cellular and molecular mechanisms underlying the pathogenesis of hepatic fibrosis. (Editor: Ralf Weiskirchen). MDPI, Basel, Beijing, Wuhan, Barcelona, Belgrade, Manchester, Tokyo, Cluj, Tianjin. pp. 1- 23. ISBN 978-3-03936-188-5.

* Ernst L, Zieglowski L, Schulz M, Moss M, Meyer M, Weiskirchen R, Palme R, Hamann M, Talbot SR, Tolba RH. Severity assessment in mice subjected to carbon tetrachloride. In: Sci Rep, 2020, 10(1):15790.

* Evliyaoglu O, Imöhl M, Weiskirchen R, van Helden J. Age-specific reference values improve the diagnostic performance of AMH in polycystic ovary syndrome. In: Clin Chem Lab Med, 2020, 58, S. 1291-1301.

* Hahn L, Helmrich N, Herebian D, Mayatepek E, Drebber U, Domann E, Olejniczak S, Weigel M, Hain T, Rath T, Wirtz S, Mollenkopf HJ, Schmidt N, Ewers C, Baier A, Churin Y, Windhorst A, Weiskirchen R, Steinhoff U, Roeb E, Roderfeld M. IL-13 as target to reduce cholestasis and dysbiosis in Abcb4 knockout mice. In: Cells 2020, 9, 1949.

* Hermert D, Martin IV, Reiss LK, Liu X, Breitkopf DM, Reimer KC, Alidousty C, Rauen T, Floege J, Ostendorf T, Weiskirchen R, Raffetseder U. The nucleic acid binding protein YB-1-controlled expression of CXCL-1 modulates kidney damage in liver. In: Kidney Int, 2020, 97, S. 741-752.

* Kim P, Zhang CC, Thoröe-Boveleth S, Weiskirchen S, Gaisa NT, Buhl EM, Stremmel W, Merle U, Weiskirchen R. Accurate measurement of vopper overload in an experimental model of Wilson disease by laser ablation inductively coupled plasma mass spectrometry. In: Biomedicines, 2020,8:356.

* Krenkel O, Hundertmark J, Ritz TP, Weiskirchen R, Tacke F. Single cell RNA sequencing identifies subsets of hepatic stellate cells and myofibroblastsin liver fibrosis. In: Cellular and molecular mechanisms underlying the pathogenesis of hepatic fibrosis. (Editor: Ralf Weiskirchen). MDPI, Basel, Beijing, Wuhan, Barcelona, Belgrade, Manchester, Tokyo, Cluj, Tianjin. pp. 85-94. ISBN 978-3-03936-188-5.

* Levada K, Omelyanchik A, Rodionova V, Weiskirchen R, Bartneck M. Magnetic-assisted treatment of liver fibrosis. In: Cellular and molecular mechanisms underlying the pathogenesis of hepatic fibrosis. (Editor: Ralf Weiskirchen). MDPI, Basel, Beijing, Wuhan, Barcelona, Belgrade, Manchester, Tokyo, Cluj, Tianjin. pp. 219-244. ISBN 978-3-03936-188-5.

* Meurer SK, Karsdal MA, Weiskirchen R. Advances in the clinical use of collagen as biomarker of liver fibrosis. In: Expert Rev Mol Diagn, 2020, 20, S. 947-969.

* Meurer SK, Tezcan O, Lammers T, Weiskirchen R. Differential regulation of Lipocalin 2 (LCN2) in doxorubicin-resistant 4T1 triple negative breast cancer cells. In: Cell Signal, 2020,74:109731.

* Meurer, SK, Weiskirchen R. Endoglin, an ’accessory’ receptor regulating blood cell development and inflammation. In: Int J Mol Sci, 2020, 21:9247.

* Roderfeld M, Padem S, Lichtenberger J, Quack T, Weiskirchen, R , Longerich T, Schramm G, Churin Y, Irungbam K, Tschuschner A, Windhorst A, Grevelding CG, Roeb E. Schistosoma mansoni egg-secreted antigens activate HCC-associated transcription factors c-Jun and STAT3 in hamster and human hepatocytes. In: Hepatology, 2020, 72, S. 626-641.

* Schröder SK, Asimakopoulou A, Tillmann S, Koschmieder SK, Weiskirchen R. TNF-α controls Lipocalin-2 expression in PC-3 prostate cancer cells. In: Cytokine, 2020, 135:155214.

* Schwinghammer U, Melkonyan MM, Hunanyan L, Tremmel R, Weiskirchen R, Borkham-Kamphorst E, Schaeffler E, Seferyan T, Mikulits W, Yenkoyan K, Schwab M, Danielyan L. α2-adrenoreceptor in liver fibrosis: implication for adrenoblocker mesedin. In: Cells, 2020, 9:456.

* Sommer J, Dorn C, Gäbele E, Bataille F, Freese K, Seitz T, Thasler WE, Büttner R, Weiskirchen R, Bosserhoff A, Hellerbrand C. Four-and-a-half LIM-domain protein 2 (FHL2) deficiency aggravates cholestatic liver injury. In: Cells, 2020, 9, 248.

* Stremmel W, Weiskirchen R, Melnik BC. Milk exosomes prevent intestinal inflammation in a genetic mouse model of ulcerative colitis: a pilot experiment. In: Inflamm Intest Dis, 2020, 5, S. 117-123.

* ten Hove MT, Pater L, Storm G, Weiskirchen S, Weiskirchen R, Lammers T, Bansal R. Hepatic lipidome: from basic science to clinical translation. In: Adv Drug Deliv Rev, 2020, 159, S. 180-197.

* Torres S, Abdullah Z, Brol MJ, Hellerbrandt C, Fernandez M, Fiorotto R, Klein S, Königshofer P, Liedtke C, Lotersztajn S, Nevzorova YA, Schierwagen R, Reiberger T, Uschner FE, Tacke F, Weiskirchen R, Trebicka J. Recent advances in practical methods for liver cell biology: a short overview. In: Int J Mol Sci, 2020, 21, 2027.

* Torres S, Abdullah Z, Brol MJ, Hellerbrandt C, Fernandez M, Fiorotto R, Klein S, Königshofer P, Liedtke C, Lotersztajn S, Nevzorova YA, Schierwagen R, Reiberger T, Uschner FE, Tacke F, Weiskirchen R, Trebicka J. Practical methods for liver cell biology. Encyclopedia, 2020, v1, Available online: encyclopedia.pub/item/revision/0c746ec1ace474f128f9ec8f303a1d9c

* van Helden J, Evliyaoglu O, Küberl A, Weiskirchen R. Disorders of the glucose metabolism correlate with the phenotype and the severity in women with polycystic ovary syndrome. In: Clin Endocrinol, 2020, 93, S. 44-51.

* Weiper K, Weiskirchen S, Weiskirchen R. From bad food to overweight: prevention of childhood obesity. In: Front Young Minds, 2020, 8:92.

* Weiskirchen R. Severity of COVID-19: Does surfactant matter? In: Front Microbiol, 2020, 11:1905.

* Weiskirchen R. Cellular and molecular mechanisms underlying the pathogenesis of hepatic fibrosis. (Editor: Ralf Weiskirchen). MDPI, Basel, Beijing, Wuhan, Barcelona, Belgrade, Manchester, Tokyo, Cluj, Tianjin. ISBN 978-3-03936-188-5.

* Weiskirchen R. Special issue on “Cellular and molecular mechanisms underlying the pathogenesis of hepatic fibrosis. In: Cells, 2020, 9:1105.

* Weiskirchen R, Meurer SK, Liedtke C, Huber M. Mast cells in liver fibrogenesis. In: Cellular and molecular mechanisms underlying the pathogenesis of hepatic fibrosis. (Editor: Ralf Weiskirchen). MDPI, Basel, Beijing, Wuhan, Barcelona, Belgrade, Manchester, Tokyo, Cluj, Tianjin. pp. 133-165. ISBN 978-3-03936-188-5.

* Weiskirchen S, Weiper K, Tolba R, Weiskirchen R. All you can feed: some comments on production of mouse diets used in biomedical research with special emphasis on non-alcoholic fatty liver disease research. In: Nutrients, 2020, 12:163.

* Winkler I, Bitter C, Winkler S, Weichenhan D, Thavamani A, Hengstler JG, Borkham-Kamphorst E, Kohlbacher O, Plass C, Geffers R, Weiskirchen R, Nordheim A. Identification of Pparγ-modulated miRNA hubs that target the fibrotic tumor microenvironment. In: Proc Natl Acad Sci USA, 2020, 117, S. 454-463.

* Wirtz TH, Buendgens L, Weiskirchen R, Loosen SH, Haehnsen N, Puengel T, Jhaisha SA, Brozat JF, Hohlstein P, Koek G, Eisert A, Mohr R, Roderburg C, Luedde T, Trautwein C, Tacke F, Koch A. Association of serum Calprotectin concentrations with mortality in critically ill and septic patients. In: Diagnostics, 2020, 10:990.

* Wirtz TH, Loosen SH, Buendgens L, Kurt B, Abu Jhaisha S, Hohlstein P, Brozat JF, Weiskirchen R, Trautwein C, Luedde T, Tacke F, Roderburg C, Koch A, Low Myostatin serum levels are associated with poor outcome in critically ill patients. In: Diagnostics 2020, 10(8):E574.

* Xie J, Weiskirchen R. What does the 'AKT' stand for in the name 'AKT kinase'?: Some historical comments”. In: Front Oncol, 2020, 10:1329.

* Asimakopoulou A, Vucur M, Luedde T, Schneiders S, Kalampoka S, Weiss TS, Weiskirchen R. Perilipin 5 and Lipocalin 2 expression in hepatocellular carcinoma. In: Cancers 2019, 11(3), 385.

* Borkham-Kamphorst E, Van de Leur E, Haas U, Weiskirchen R. Liver parenchymal cells lacking Lipocalin 2 (LCN2) are prone to endoplasmic reticulum stress and unfolded protein response. In: Cell Signal, 2019, 55, S. 90-99.

* Cuppari A, Koerschgen H, Fahrenkamp D, Schmitz C, Guevara T, Karmilin K, Kuske M, Olf M, Dietzel E, Yiallouros I, de Sanctis D, Goulas T, Weiskirchen R, Jahnen-Dechent W, Floehr J, Stoecker W, Jovine L, Gomis-Rueth FX. Structure of mammalian plasma fetuin-B and its mechanism of selective metallopeptidase inhibition. In: IUCrJ, 2019, 6, S. 317-330.

* Drescher HK, Brandt EF, Fischer P, Dreschers S, Schwendener RA, Kowalska MA, Canbay A, Wasmuth HE, Weiskirchen R, Trautwein C, Berres ML, Kroy DC, Sahin H. Platelet factor 4 attenuates experimental acute liver injury in mice. In: Front Physiol. 2019;10:326.

* Drescher HK, Weiskirchen R, Fülöp A, Hopf C, Gonzáles de San Roman E, Huesgen PF, de Bruin A, Christ A, Tolba R, Trautwein C, Kroy DC. The influence of different fat sources on steatohepatitis and fibrosis development in the Western diet mouse model of non-alcoholic steatohepatitis (NASH). In: Front Physiol, 2019, 10:770.

* Drescher HK, Weiskirchen S, Weiskirchen R. Current status in testing for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). In: Cells, 2019, 8, 845.

* Evliyaoglu O, van Helden J, Imöhl M, Weiskirchen R. Mining the age-dependent reference intervals of B vitamins from routine laboratory test results. In: Lab Med, 2019, 50, S. 54-63.

* Evliyaoglu O, van Helden J, Imöhl M, Weiskirchen R. Vitamin B1 interpretation: Erroneous higher levels in non-anemic population. In: Nutrition, 2019, 60, S. 25-29.

* Evliyaoglu O, van Helden J, Jaruschewski S, Imöhl M, Weiskirchen R. Reference change values of M-protein, free light chain and immunoglobulins in monoclonal gammopathy. In: Clin Biochem, 2019, 74, S. 42-46.

* Fiegle E, Doleschel D, Koletnik S, Rix A, Weiskirchen R, Borkham-Kamphorst E, Kiessling F, Lederle W. Dual CTLA-4 and PD-L1 blockade inhibits tumor growth and liver metastasis in a highly aggressive orthotopic mouse model of colon cancer. In: Neoplasia, 2019, 21, S. 932-944.

* Hansel C, Erschfeld S, Baues M, Lammers T, Weiskirchen R, Trautwein C, Kroy DC, Drescher HK. The inhibitory T cell receptors PD1 and 2B4 are differentially regulated on CD4 and CD8 T cells in a mouse model of non-alcoholic steatohepatitis. In: Front Pharmacol, 2019,10:244.

* Hassan R, Tammam SN, El Safy S, Abdel-Halim M, Asimakopoulou A, Weiskirchen R, Mansour S. Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis. ‎In: Eur J Pharm Biopharm, 2019, 134, S. 96-106.

* Iwasaki J, Afify M, Bleilevens C, Klinge U, Weiskirchen R, Steitz J, Vogt M, Yagi S, Nagai K, Uemoto S, Tolba RH. The impact of a nitric oxide synthase inhibitor (L-NAME) on ischemia-reperfusion injury of cholestatic livers by Pringle Maneuver and liver resection after bile duct ligation in rats. In: Int J Mol Sci, 2019, 20, 2114.

* Karmilin K, Schmitz C, Kuske M, Körschgen H, Olf M, Meyer K, Hildebrand A, Felten M, Fridrich S, Yiallouros I, Becker-Pauly C, Weiskirchen R, Floehr J, Jahnen-Dechent W, Stöcker W. Mammalian plasma fetuin-B is a selective inhibitor of ovastacin and meprin metalloproteinases. In: Sci Rep, 2019, 9:546.

* Krenkel O, Hundertmark J, Ritz TP, Weiskirchen R, Tacke T. Single cell RNA sequencing identifies subsets of hepatic stellate cells and myofibroblasts in liver fibrosis. In: Cells, 2019, 8, 503.

* Levada K, Omelyanchik A, Rodionova V, Weiskirchen R, Bartneck M. Magnetic-assisted treatment of liver fibrosis. In: Cells, 2019, 8, 1279.

* Mahli A, Seitz T, Beckröge T, Freese K, Thasler WE, Benkert M, Dietrich P, Weiskirchen R, Bosserhoff A, Hellerbrand C. Bone morphogenetic protein-8B expression is induced in steatotic hepatocytes and promotes hepatic steatosis and inflammation in vitro. In: Cells, 2019, 8, 457.

* Mahli A, Seitz T, Fresse K, Frank J, Weiskirchen R, Abdel-Tawab M, Behnam D, Hellerbrand C. Therapeutic application of micellar solubilized xanthohumol in a Western-type diet-induced mouse model of obesity, diabetes and non-alcoholic fatty liver disease. In: Cells, 2019, 8, 359.

* Meurer SK, Wimmer AE, van de Leur E, Weiskirchen R. Endoglin trafficking/exosomal targeting in liver cells depends on N-glycosylation. In: Cells, 2019, 8, 997.

* Olivier LS, Evliyaoglu O, Weiskirchen R, van Helden J. Investigation of soluble anti-Müllerian hormone receptor type 2 as a biomarker for diagnosis of female fertility disorders. In: Reprod BioMed Online, 2019, 39, S. 1017-1025.

* Pinheiro D, Dias I, Silva KR, Stumbo AC, Thole A, Cortez E, de Carvalho L, Weiskirchen R, Carvalho S. Mechanisms underlying cell therapy in liver fibrosis: an overview. In: Cells, 2019, 8, 1339.

* Ranjbar Taklimie FR, Gasterich N, Scheld M, Weiskirchen R, Beyer C, Clarner T, Zendedel A. Hypoxia induces astrocyte-derived Lipocalin-2 in ischemic stroke. In: Int J Mol Sci, 2019, 20(6), 1271.

* Reuner U, Stremmel W, Weiskirchen R. The interesting case - Orphan diseases - double trouble. In: Annals Transl Med, 2019, 7(Suppl 2): S74.

* Stremmel W, Merle U, Weiskirchen R. Clinical features of Wilson disease. In: Annals Transl Med, 2019, 7(Suppl 2): S61.

* Stremmel W, Staffer S, Frickert G, Weiskirchen R. The bile acid-phospholipid conjugate ursodeoxycholyl-lysophosphatidylethanolamide (UDCA-LPE) disintegrates the lipid backbone of raft plasma membrane domains by the removal of the membrane phospholipase A2. In: Int J Mol Sci, 2019, 20, 5631.

* Stremmel W, Staffer SG, Weiskirchen R. Phosphatidylcholine passes by paracellular transport to the apical side of the polarized biliary tumor cell line Mz-ChA-1. In: Int J Mol Sci, 2019, 20, 4034.

* Sun Q, Baues M, Klinkhammer BM, Ehling J, Djudjaj S, Drude NI, Daniel C, Amann K, Kramann R, Kim H,  Saez-Rodriguez J, Weiskirchen R, Onthank DC, Botnar RM, Kiessling F, Floege J, Lammers T, Boor P. Elastin imaging enables non-invasive staging and treatment monitoring of kidney fibrosis. In: Sci Transl Med, 2019, 486, eaat4865.

* van der Heide D, Weiskirchen R, Bansal R. Therapeutic targeting of hepatic macrophages for the treatment of liver disease. In: Front Immunol, 2019, 10: 2852.

* van Helden J, Evliyaoglu O, Dreßen D, Weiskirchen R. A new free light chain immunoassay shows advantages in the classification and in the follow-up of patients with paraproteinemia compared to a nephelometric assay. Hematol & Med Oncol, 2019, 4, S. 1-7.

* van Helden J, Evliyaoglu O, Weiskirchen R. Has GnRH a direct role in AMH regulation? In: Clin Endocrinol, 2019, 90, S. 827-833.

* van Roeyen CRC, Martin IV, Drescher A, Schuett KA, Hermert D, Raffetseder U, Otten S, Buhl EM, Braun G, Kuppe C, Liehn E, Boor P, Weiskirchen R, Eriksson U, Gross O, Eitner F, Floege J, Ostendorf T. Identification of platelet-derived growth factor C as a mediator of both renal fibrosis and hypertension. In: Kidney Int, 2019, 95, S. 1103-1119.

* Weiskirchen R. Montelukast prevents mice against acetaminophen-induced liver injury (Commentary). In: Front Pharmacol, 2019, 10:1289.

*Weiskirchen R, Meurer SK, Liedtke C, Huber M. Mast cells in liver fibrogenesis. In: Cells, 2019, 8, 1429.

* Weiskirchen R, Stremmel W. Wilson disease: current knowledge, challenges and perspectives. Preface to the Focused Issue “Wilson’s disease: from genetics to management of disease” (Eds. Ralf Weiskirchen & Wolfgang Stremmel). In: Annals Transl Med, 2019, 7(Suppl 2): S55.

* Weiskirchen R, Tacke F. Hepatic Fibrogenesis. In: Reference Module in Biomedical Sciences, 2019, S. 1-7. 10.1016/B978-0-12-801238-3.65705-7.

* Weiskirchen R, Tacke F. Relevance of autophagy in parenchymal and non-parenchymal liver cells for health and disease. In: Cells, 2019, 8, 16.

* Weiskirchen R, Weiskirchen S, Kim P, Winkler R. Software solutions for evaluation and visualization of laser ablation inductively coupled plasma mass spectrometry imaging (LA-ICP-MSI) data: a short overview. In: J Cheminform, 2019, 11:16.

* Weiskirchen R, Weiskirchen S, Tacke F. Organ and tissue fibrosis: molecular signals, cellular mechanisms and translational implications. In: Mol Aspects Med, 2019, 65, S. 2-15.

* Weiskirchen S, Kim P, Weiskirchen R. Determination of copper poisoning in Wilson’s disease using laser ablation inductively coupled plasma spectrometry. In: Annals Transl Med, 2019, 7(Suppl 2): S72.

* Weiskirchen S, Kim P, Weiskirchen R. Laser ablation inductively coupled plasma spectrometry: metal imaging in experimental and clinical Wilson Disease. In: Inorganics, 2019, 7, 54.

* Yagmur E, Bast E, Mühlfeld AS, Koch A, Weiskirchen R, Tacke F, Neulen J. High prevalence of sticky platelet syndrome in patients with infertility and pregnancy loss. In: J Clin Med, 2019, 8, 1328.

* Yagmur E, Buergerhausen D, Koek GH, Weiskirchen R, Trautwein C, Koch A, Tacke F. Elevated CTRP1 plasma concentration is associated with sepsis and pre-existing type 2 diabetes mellitus in critically ill patients. In: J Clin Med, 2019, 8, 661.

* Yagmur E, Otto S, Koek GH, Weiskirchen R, Trautwein C, Koch A, Tacke F. Decreased CTRP3 plasma concentrations are associated wtih sepsis and predict mortality in critically ill patients. In: Diagnostics, 2019, 9(2):63.

* Yagmur E, Sckaer JH, Koek GH, Weiskirchen R, Trautwein C, Koch A, Tacke F. Elevated MR-proANP plasma concentrations are associated with sepsis and predict mortality in critically ill patients. In: J Transl Med, 2019, 17:415.

* Alsamman M, Sterzer V, Meurer SK, Sahin H, Schaeper U, Kuscuoglu D, Strnad P, Weiskirchen R, Trautwein C, Scholten D. Endoglin in human liver disease and murine models of liver fibrosis - a protective factor against liver fibrosis. In: Liver Int, 2018, 38, S. 858-867.

* Borkham-Kamphorst E, Van de Leur E, Buhl, EM, Meurer SK, Weiskirchen R. N-glycosylation of Lipocalin 2 is not required for secretion or exosome targeting. In: Front Physiol, 2018, 9:426.

* Borkham-Kamphorst E, Steffen BT, van de Leur E, Haas U, Weiskirchen R. Portal myofibroblasts are sensitive to CCN-mediated endoplasmic reticulum stress-related apoptosis with potential to attenuate biliary fibrogenesis. In: Cell Signal, 2018, 51, S. 72-85.

* Gauthier A, Fisch A, Seuwen K, Baumgarten B, Ruffner H, Aebi A, Rausch M, Bartneck M, Weiskirchen R, Tacke F, Storm G, Lammers T, Ludwig M-G. Glucocorticoid-loaded liposomes induce a pro-resolution phenotype in human primary macrophages to support chronic wound healing. In: Biomaterials, 2018, 178, S.481-495.

* Jenkitkasemwong S, Akinyode N, Paulus E, Weiskirchen R, Hojyo S, Fukada T, Giraldo G, Schrier J, Garcia A, Janus C, Giasson B, Knutson M D. SLC39A14 deficiency alters manganese homeostasis and excretion resulting in brain manganese accumulation and motor deficits in mice. In: Proc Natl Acad Sci USA, 2018, 115, E1769-E1778.

* Kim P, Weiskirchen S, Uerlings R, Kueppers A, Stellmacher F, Viveiros A, Zoller H, Weiskirchen R. Quantification of liver iron overload disease with laser ablation inductively coupled plasma mass spectrometry. In: BMC Med Imaging, 2018, 18:51.

* Koch A, Weiskirchen R, Krusch A, Bruensing J, Buendgens L, Herbers U, Yagmur E, Koek GH, Trautwein C, Tacke F. Visfatin serum levels predict mortality in critically ill patients. In: Dis Markers, 2018, 2018:7315356.

* Koch A, Yagmur E, Hoss A, Buendgens L, Herbers U, Weiskirchen R, Koek GH, Trautwein C, Tacke F. Clinical relevance of copeptin plasma levels as a biomarker of disease severity and mortality in critically ill patients. In: J Clin Lab Anal, 2018, e22614.

* Koch A, Yagmur E, Linka J, Schumacher F, Bruensing J, Buendgens L, Herbers U, Koek GH, Weiskirchen R, Trautwein C, Tacke F. High circulating caspase-cleaved keratin 18 fragments (M30) indicate short-term mortality in critically ill patients. In: Dis. Markers, 2018, 2018:8583121.

* Krenkel O, Puengel T, Govaere O, Abdallah AT, Mossanen JC, Kohlhepp M, Liepelt A, Lefebvre, E, Luedde T, Hellerbrand C, Weiskirchen R, Longerich T, Costa IG, Anstee QM, Trautwein C, Tacke F. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. In: Hepatology 2018, 67, S. 1270-1283.

* Lenk L, Pein M, Will O, Gomez B, Viol F, Hauser C, Egberts JH, Gundlach P, Tiwari S, Weiskirchen R, Rose-John S, Röcken C, Mikulits W, Wenzeli P, Schneider G, Saur D, Schäfer H, Sebens S. The hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma. In: OncoImmunology, 2018, 7(1):e1368603.

* Matriciani B, Huppertz B, Keller R, Weiskirchen R. False negative results in the immunoassay analysis of drugs of abuse: can adulterants be detected by sample check test? In: Ann Clin Biochem, 2018, 55, S. 348-354.

* Meurer SK, Weiskirchen R. Activation by inhibition. In: Atlas of Science, 2018 (July 9). https://atlasofscience.org/activation-by-inhibition/

* Meurer SK, Weiskirchen R. Usage of Mitogen-Activated Protein Kinase small inhibitors: More than just inhibition! In: Front Pharmacol, 2018, 9:98.

* Moreno D, Murillo O, Gazquez C, Hernandez-Alcoceba R, Uerlings R, Gonzalez-Aseguinolaza G, Weiskirchen R. Visualization of the therapeutic efficacy of a gene correction approach in Wilson's disease by laser-ablation inductively coupled mass spectrometry. In: J Hepatol 2018, 68, S. 199-201.

* Orpen A. F1000Primeblog. What do our Faculty Members think about Peer Review? With comments from Faculty Members G. Kaspers, E. Morales, T. Galli, N. Young, R. Weiskirchen, and Y. Che. In: https://blog.f1000.com/2018/09/13/what-do-our-faculty-members-think-about-peer-review/

* Rose M, Meurer SK, Kloten V, Weiskirchen R, Denecke B, Antonopoulos W, Deckert M, Knüchel R, Dahl E. ITIH5 induces a shift in TGF-β superfamily signaling involving Endoglin and reduces risk for breast cancer metastasis and tumor death. In: Mol Carcinog, 2018, 57, S. 167-181.

* Schröder SK, Asimakopoulou A, Weiskirchen A. Lipocalin 2 as a potential diagnostic and/or prognostic biomarker in prostate, lung and liver cancer. In: Clinics of Oncology, 2018, 1(3):1-16. http://clinicsofoncology.com/pdf/COO-v1-1011.pdf

* Sonntag R, Giebeler N, Nevzorova YA, Bangen JM, Fahrenkamp D, Lambertz D, Haas U, Hu W, Gassler N, Cubero FJ, Müller-Newen G, Abdallah AT, Weiskirchen R, Ticconi F, Costa IG, Barbacid M, Trautwein C, Liedtke C. Cyclin E1 and Cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma. In: Proc Natl Acad Sci USA, 2018, 115, S. 9282-9287.

* Tacke F, Weiskirchen R. An update on the recent advances in antifibrotic therapies. In: Exp Rev Gastroenterol Hepatol, 12(11), S. 1143-1152.

* Ullmann P, Rodriguez F, Schmitz M, Meurer SK, Qureshi-Baig K, Felten P, Ginolhac A, Antunes L, Frasquilho S, Zügel N, Weiskirchen R, Haan S, Letellier E. The microRNA-371~373 cluster represses colon cancer initiation and metastatc colonization by inhibiting the TGFBR2/ID1 signaling axis. In: Cancer Res, 2018, 78, S. 3793-3808.

* Uerlings R, Moreno D, Murillo O, Gazquez C, Hernandez-Alcoceba R, Gonzalez-Aseguinolaza G, Weiskirchen R. Brain copper storage after genetic long-term correction in a mouse model of Wilson disease. In: Neurol Genet, 2018, 4:e243.

* van Helden J, Weiskirchen R. Cross-method comparison of serum androstenedione measurement with respect to the validation of a new fully automated chemiluminescence immunoassay. In: Clin Biochem, 2018, 62, S. 32-38.

* van Helden J, Weiskirchen R. Technical and diagnostic performance of a new fully automated immunoassay for the determination of intact fibroblast growth factor 23 (FGF23). In: Scand J Clin Lab Invest, 2018, 78, S. 584-590.

* Weiskirchen, R. AG Weiskirchen. In: ScieGuide Aachen 2018, Überblick über die Forschung an der RWTH Aachen und an Instituten in Aachen und Umgebung. btS Die Life Sciences Studenteninitiative, 2018, S. 78-79.

* Weiskirchen R, Tacke F. The role of radiologic modalities in diagnosing non-alcoholic steatohepatitis (NASH) and fibrosis. In: Curr Hepat Rep, 2018, 17, S. 324-335.

* Weiskirchen R, Weiskirchen S, Tacke F. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. In: F1000Res, 2018:921.

* Weiskirchen, S., Weiskirchen, R. Ultrapure cells for liver research. In: Atlas of Science, 2018 (May 30). https://atlasofscience.org/ultrapure-cells-for-liver-research/

* Weiskirchen S, Weiskirchen R. Birnen Vielfalt (Leserbrief). In: Kraut & Rüben, 2018. https://www.krautundrueben.de/leserbrief-birnen-vielfalt

* Weiskirchen S, Weiskirchen R. A novel quantitative iron imaging strategy in hereditary hemochromatosis based on LA-ICP-MS. In: Atlas of Science, 2018 (December 20). http://atlasofscience.org/a-novel-quantitative-iron-imaging-strategy-in-hereditary-hemochromatosis-based-on-la-icp-ms/

* Yagmur E, Buendgens L, Herbers U, Beeretz A, Weiskirchen R, Koek GH, Trautwein C, Tacke F, Koch A. High-mobility group box 1 as a biomarker in critically ill patients. In: J Clin Lab Anal, 2018, e22584.

* Asimakopoulou A, Fülöp A, Borkham-Kamphorst E, Van de Leur E, Gassler N, Berger T, Beine B, Meyer HE, Mak TW, Hopf C, Henkel C, Weiskirchen R. Altered mitochondrial and peroxisomal integrity in lipocalin-2-deficient mice with hepatic steatosis. In: BBA Mol Bas Dis, 2017, 1863, S. 2093-2110.

* Asimakopoulou A, Borkham-Kamphorst E, Van de Leur E, Weiskirchen R. Data on Lipocalin 2 and phosphatidylinositol 3-kinase signaling in a methionine- and choline-deficient model of non-alcoholic steatohepatitis. In: Data in Brief, 2017, 13, S. 644-649.

* Asimakopoulou A, Weiskirchen S, Weiskirchen R. Pathogenesis, diagnostic and treatment of hereditary hemochromatosis: a 150 years long understanding of an iron overload disorder. In: EMJ Hepatology 2017, 2(4), 122-133.

* Dietzel, E, Weiskirchen, S, Floehr, J, Horiguchi, M, Todorovic, V, Rifkin, DB, Jahnen-Dechent, W, Weiskirchen, R. Latent TGF-β binding protein-1 deficiency decreases female fertility. In: Biochem Biophys Res Commun, 2017, 482, S. 1387-1392.

* Dietzel E, Floehr J, Van de Leur E, Weiskirchen R, Jahnen-Dechent W. Recombinant fetuin-B protein maintains high fertility rate in cumulus cell-free mouse oocytes. In: Mol Hum Reprod, 2017, 23, S. 25-33.

* Iliodromiti S, Salje B, Dewailly D, Fairburn C, Fanchin R, Fleming R, Wun H, Li R, Lukaszuk K, Ng EH, Pigny P, Tadros T, van Helden J, Weiskirchen R, Nelson SM. Non-equivalence of anti-Müllerian hormone automated assays - clinical implications for use as a companion diagnostic for individualised gonadotrophin dosing. In: Hum Reprod, 2017, 32, S. 1710-1715.

* Koch A, Weiskirchen R, Ludwig S, Buendgens L, Bruensing J, Yagmur E, Baeck C, Herbers U, Trautwein C, Tacke F. Relevance of serum sclerostin concentrations in critically ill patients. In: J. Crit Care, 2017, 37, S. 38-44.

* Lambertz J, Berger T, Mak TW, van Helden J, Weiskirchen R. Lipocalin-2 in fructose-induced fatty liver disease. In: Front Physiol 2017, 8:964.

* Lambertz J, Weiskirchen S, Landert S, Weiskirchen R. Fructose: A dietary sugar in crosstalk with microbiota contributing to the development and progression of non-alcoholic liver disease. In: Front Immunol, 2017, S. 8:1159.

* Ma Y, Li Q, Li A, Wei Y, Long P, Jiang X, Sun F, Weiskirchen R, Wu B, Liang C, Grötzinger J, Wei Y, Yu W, Mercola M, Huang Y, Wang J, Yu Y, Schwartz RJ. The CSRP2BP histone acetyltransferase drives smooth muscle gene expression. In: Nucleic Acids Res, 2017, 45, S. 3046-3058.

* Maywald M, Meurer SK, Weiskirchen R, Rink L. Zinc supplementation augments TGF-β1 dependent regulatory T cell induction. In: Mol Nutr Food Res, 2017, S. 61(3):1600493.

* Meurer SK, Weiskirchen R. Endoglin (ENG). In: Encyclopedia of Signaling Molecules, 2nd Edition (Springer) 2017, Ed. S. Choi, ISBN: 978-1-4419-0460-7 (Print) 978-1-4419-0461-4 (Online), S.1-14. doi 10.1007/978-1-4614-6438-9_101593-1.

* Rose M, Kloten V, Noetzel E, Gola L, Ehling J, Heide T, Meurer SK, Gaiko-Shcherbak A, Sechi AS, Huth S, Weiskirchen R, Klaas O, Antonopoulos W, Lin Q, Wagner W, Veeck J, Gremse F, Steitz J, Knüchel R, Dahl E. ITIH5 mediates epigenetic reprogramming of breast cancer cells. In: Mol Cancer, 2017, S. 16(1):44.

* Sipouo S, Mucke G, Huppertz B, Riedel M, Weiskirchen R, Keller R, Weiskirchen R. False negative results in testing for drugs of abuse from diluted urine. In: Int J Clin Chem Lab Med, 2017, 3, S. 9-17.

* Uerlings R, Weiskirchen R. An at-a-glance visualization of regional metal accretion in tissue samples by image overlay in laser ablation inductively coupled plasma mass spectrometry. In: 2017, Laser Ablation: Advances in Research and Applications is approaching. (Ed. C. Bellucci). Nova Science Publishers, Inc., New York, S. 87-113. Available as Hardcover (ISBN: 978-1-53612-405-7) and eBook (ISBN: 978-1-53612-408-8).

* van Helden J, Weiskirchen R. Association of age-independent Anti-Müllerian hormone (AMH) standard deviation scores to ovarian function. In: Eur J Obstet Gynecol Reprod Biol, 2017, 213, S. 64-70.

* Weiskirchen R, Tacke F. Interleukin-33 in the pathogenesis of liver fibrosis: alarming ILC2 and hepatic stellate cells. In: Cell Mol Immunol, 2017, 14, S. 143-145.

* Weiskirchen, R., Tacke, F. Combining GP73 with liver stiffness measurements: A proof-of-concept for non-invasive fibrosis assessment in antiviral-naive HBV patients. In: Liver Int, 2017, 37, S. 1605-1607.

* Weiskirchen R. Fast progression of liver damage in lysosomal acid lipase deficiency. In: Curr Med Res Opin, 2017, 33, S. 2081-2083.

* Weiskirchen R. Therapeutic targeting of the mitochondrial reactive oxygen species engine prevents portal hypertension and hepatic fibrogenesis. Liver Int, 2017, 37, S. 963-965.

* Weiskirchen R. Lipopolysaccharide-induced acute phase response: new views on trace metal plasticity in hepatic inflammation. In: 2017, Glob Imaging Insights 3, S. 1-3.

* Weiskirchen R. Preface. In: 2017. Key leaders' opinion on precision medicine in hepatobiliary cancer (English version). H. Zhao & R. Weiskirchen (Eds). AME Publishing Company. Hong Kong, Hangzhou, Guangzhou. ISBN-10: 9887784168 / ISBN-13: 978-9887784166.

* Weiskirchen R. Intratumor heterogeneity, variability and plasticity: questioning the current concepts in classification and treatment of hepatocellular carcinoma. In: 2017, Key leaders' opinion on precision medicine in hepatobiliary cancer (English version). H. Zhao & R. Weiskirchen (Eds). AME Publishing Company. Hong Kong, Hangzhou, Guangzhou, China, S. 17-21. ISBN-10: 9887784168 / ISBN-13: 978-9887784166.

* Weiskirchen R. Preface to Second Edition. In: Encyclopedia of Signaling Molecules, 2nd Edition (Springer) 2017, Ed. S. Choi, ISBN: 978-3-319-67198-7 (Print) 978-3-319-67199-4 (Online), S. vi.

* Weiskirchen S, Tag CG, Sauer-Lehnen S, Tacke F, Weiskirchen R. Isolation and culture of primary murine hepatic stellate cells. In: Methods Mol Biol, 2017, 1627, S. 165-191. Available as Hardcover (ISBN: 978-1-4939-7112-1) and eBook (ISBN: 978-1-4939-7113-8).

* Weiskirchen S, Weiskirchen R. Resveratrol: Is it really good for liver health? In: Hepat Mon, 2017, 17(8):e12074.

* Asimakopoulou A, Borkham-Kamphorst E, Tacke F, Weiskirchen R. Lipocalin-2 (NGAL/LCN2), a "HELP-ME" signal in organ inflammation. In: Hepatology, 2016, 63, S.669-671.

* Asimakopoulou A, Weiskirchen S, Weiskirchen R. Lipocalin 2 (LCN2) expression in hepatic malfunction and therapy. In: Front Physiol, 2016, 9:430.

* Borkham-Kamphorst E, Steffen BT, Van de Leur E, Tihaa L, Haas U, Woitok MM, Meurer SK, Weiskirchen R. Adenoviral CCN gene transfers induce in vitro and in vivo endoplasmic reticulum stress and unfolded protein response. In: Biochim Biophys Acta, 2016, 1863, S. 2604-2612.

* Borkham-Kamphorst E, Steffen BT, van de Leur E, Haas U, Tihaa L, Friedman SL, Weiskirchen R. CCN1/CYR61 overexpression in hepatic stellate cells induces ER stress-related apoptosis. In: Cell Signal, 2016, 28, S. 34-42.

* Borkham-Kamphorst E, Weiskirchen R. The PDGF system and its antagonists in liver fibrosis. In: Cytokine Growth Factor Rev 2016, 28C, S. 53-61.

* Buhl EM, Djudjaj S, Babickova J, Klinkhammer BM, Folestad E, Borkham-Kamphorst E, Weiskirchen R, Hudkins K, Alpers CE, Eriksson U, Floege J, Boor P. The role of PDGF-D in healthy and fibrotic kidneys. In: Kidney Int, 2016, 89, S. 848-861.

* Kanta J, Mrkvicová A, Weiskirchen R. Editorial: Liver myofibroblasts. In: Front Physiol, 2016, 7, 343.

* Kanta J, Mrkvicová A, Weiskirchen R. E-Book: Liver myofibroblasts(Eds. Kanta J, Mrkvicová A, Weiskirchen R. Preface. Frontiers Media SA, 2016, p. 2-4 (ISBN 978-2-88919-989-1).

* Koppe C, Verheuged P, Gautheron J, Reisinger F, Kreggenwinkel K, Roderburg C, Quagliata L, Terracciano L, Gassler N, Tolba R, Boege Y, Weber A, Karin M, Luedde M, Neumann UP, Weiskirchen R, Tacke F, Vucur M, Trautwein C, Lüscher B, Preisinger C, Heikenwälder M, Lüdde T. IKKα/β control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylation the cell death mediator receptor-interacting protein kinase 1. In: Hepatology, 2016, 64, S. 1217-1231.

* Merle U, Weiskirchen R. Wilson's disease: An inherited silent copper intoxication disease. In: EMJ Neurol, 2016, 4, S. 74-83.

* Meurer SK, Neß M, Weiskirchen S, Kim P, Tag CG, Kauffmann M, Huber M, Weiskirchen R. Isolation of mature (peritoneum-derived) mast cells and immature (bone-marrow-derived) mast cell precursors from mice. In: PLoS ONE, 2016, 11(6):e0158104.

* Schon HT, Bartneck M, Borkham-Kamphorst E, Nattermann J, Lammers T, Tacke F, Weiskirchen R. Pharmacological intervention in hepatic stellate cell activation and hepatic fibrosis. In: Front Pharmcol, 2016, 7:33.

* Schon HT, Weiskirchen R. Exercise-induced release of pharmacologically active substances and their relevance for therapy of hepatic injury. In: Front Pharmacol, 2016, 7:283.

* Susnea I, Weiskirchen R. Trace metal imaging in diagnostic of hepatic metal disease. In: Mass Spectrom Rev, 2016, 35, S. 666-686.

* Uerlings R, Matusch A, Weiskirchen R. Reconstruction of laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) spatial distribution images in Microsoft Excel 2007. In: Int J Mass Spectrom, 2016, 395, S. 27-35.

* Uerlings R, Matusch A, Weiskirchen R. Standardization and normalization of data from laser ablation inductively coupled plasma mass spectrometry. In: Applications of Laser Ablation - Thin Film Deposition, Nanomaterial Synthesis and Surface Modification (Ed. Yang D.) Intech Publishing 2016. (ISBN: 978-953-51-4892-0), S. 399-415.

* van Helden J, Weiskirchen R. Diagnostischer Wert der quantitativen HBsAg Bestimmung bei der Hepatitis B Infektion (Diagnostic value of the quantitative HBsAg determination in hepatitis B infections). In: Z Gastroenterol, 2016, 54, S. 319-326.

* Weiskirchen R. Hepatoprotective and anti-fibrotic agents: It’s time to take the next step. In: Front Pharmacol, 2016, 6:303.

* Weiskirchen R. Intratumor heterogeneity, variability and plasticity: Questioning the current concepts in classification and treatment of hepatocellular carcinoma. In: Hepatobiliary Surg Nutr, 2016, 5, S. 183-187.

* Weiskirchen R., Tacke F. Immune surveillance of liver cancer in NAFLD: Excess lipids cause CD4 T cell loss and promote HCC hepatocellular carcinoma development. In: Hepatobiliary Surg Nutr, 2016, 5, S. 433-437.

* Weiskirchen R, Tacke F. Leberfibrose: von der Pathologie zu den Therapiemöglichkeiten. In: Falk Gastro-Kolleg 2016.

* Weiskirchen R, Tacke F. Liver fibrosis: from pathogenesis to novel therapies. In: Dig Dis, 2016, 34, S. 410-422.

* Weiskirchen R, Tacke F. Liver fibrosis – which mechanisms matter? In: Clin Liver Dis, 2016, 8, S. 94-99.

* Weiskirchen R, Tacke F. Neue Therapieoptionen für die Leberfibrose: from-bench-to-bedside. In: Der Gastroenterologe, 2016, 11, S. 40-46.

* Weiskirchen S, Weiskirchen R. Resveratrol: How much wine do you have to drink to stay healthy? In: Adv Nutr, 2016, 7, S. 706-718. (Press release to this article)

* Asimakopoulou A, Weiskirchen R. Lipocalin 2 in the pathogenesis of fatty liver disease and non-alcoholic steatohepatitis. In: Clinical Lipidol, 2015, 10, S. 47-67.

* Bartneck M, Topuz F, Tag CG, Sauer-Lehnen S, Warzecha CT, Trautwein C, Weiskirchen R, Tacke F. Molecular response of liver sinusoidal endothelial cells on hydrogels. In: Mater Sci Eng C Mater Biol Appl, 2015, 51, S. 64-72.

* Bartneck M, Warzecha KT, Tag CG, Sauer-Lehnen S, Heymann F, Trautwein C, Weiskirchen R, Tacke F. Isolation and time lapse microscopy of hepatic stellate cell  activation in vitro and correlation with fibrosis in vivo. In: Anal Cell Pathol, 2015, Article ID 417023.

* Boaru SG, Borkham-Kamphorst E, Van de Leur E, Lehnen E, Liedtke C, Weiskirchen R. NLRP3 inflammasome expression is driven by NF-κB in cultured hepatocytes. In: Biochem Biophys Res Commun, 2015, 458, S. 700-6.

* Boaru SG, Merle U, Uerlings R, Zimmermann A, Willheim C, Ferenci P, Stremmel W, Weiskirchen R. Laser ablation inductively coupled plasma mass spectrometry imaging of metals in experimental and clinical Wilson's disease: In: J Cell Mol Med, 2015, 19, S. 806-14.

* Borkham-Kamphorst E, Alexi P, Tihaa L, Haas U, Weiskirchen R. Platelet-derived growth factor-D modulates extracellular matrix homeostasis and remodeling through TIMP-1 induction and attenuation of MMP-2 and MMP-9 gelatinase activities. In: Biochem Biophys Res Commun, 2015, 457, S. 307-13.

* Borkham-Kamphorst E, Meurer SK, van de Leur E, Haas U, Tihaa L, Weiskirchen R. PDGF-D signalling in portal myofibroblasts and hepatic stellate cells proves identical to PDGF-B via both PDGF receptor type α and β. In: Cell Signal 2015, 27, S. 1305-14.

* Hamesch K, Borkham-Kamphorst E, Strnad P, Weiskirchen R. Lipopolysaccharide-induced inflammatory liver injury in mice. In: Lab Animals, 2015, 49 (S1), S. 37-46.

* Heymann F, Hamesch K, Weiskirchen R, Tacke F. The Concanavalin A model of acute hepatitis in mice. In: Lab Animals, 2015, 49 (S1), S. 12-20.

* Horiguchi M, Todorovic V, Hadjiolova K, Weiskirchen R, Rifkin DB. Abrogation of both short and long forms of latent transforming growth factor-β binding protein-1 causes defective cardiovascular development and is perinatally lethal. In: Matrix Biol 2015, 43C, S. 61-70.

* Nair DG, Weiskirchen R, Al-Musharafi SK. Marine-derived bioactive compounds as potential hepatoprotective agents. In: Acta Phamacol Sinica, 2015, 36, S. 158-70.

* Ramadori P, Weiskirchen R, Trebicka J, Streetz K. Mouse models of metabolic liver injury. In: Lab Animals, 2015, 49 (S1), S. 47-58.

* Scholten D, Trebicka J, Liedtke C, Weiskirchen R. The carbon tetrachloride model in mice. In: Lab Animals, 2015, 49 (S1), S. 4-11.

* Tag CG, Sauer-Lehnen S, Weiskirchen S, Borkham-Kamphorst E, Tolba RH, Tacke F, Weiskirchen R. Bile duct ligation in mice: Induction of inflammatory liver injury and fibrosis by obstructive cholestasis. In: J Vis Exp, 2015, 94:e52438.

* Tag CG, Weiskirchen S, Hittatiya K, Tacke F, Tolba RH, Weiskirchen R. Induction of experimental obstructive cholestasis in mice. In: Lab Animals, 2015, 49 (S1), S. 70-80.

* Tolba RH, Kraus T, Liedtke C, Schwarz M, Weiskirchen R. Diethylnitrosoamine (DEN)-induced carcinogenic liver injury in mice. In: Lab Animals, 2015, 49 (S1), S. 59-69.

*Tolba RH, Riederer BM, Weiskirchen R. Standard Operating Procedures in experimental liver research: Time to achieve uniformity. In: Lab Animals, 2015, 49(S1), S. 1-3.

* van Helden J, Weiskirchen R. Experience with the first fully automated chemiluminescence immunoassay for the quantification of 1α, 25-dihydroxy-vitamin D. In: Clin Chem Lab Med, 2015, 53, S. 761-70.

* van Helden J, Weiskirchen R. Performance of the two fully automated anti-Müllerian hormone immunoassays compared with the clinical standard assay.  In: Human Reprod 2015, 30, S. 1918-26. 

* van Helden J, Weiskirchen R. Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia. In: Clin Biochem, 2015, 48, S.1113-9.

* Wallace MC, Hamesch K, Lunova M, Kim Y, Weiskirchen R, Strnad P, Friedman SL. Standard Operating Procedures in experimental liver research: Thioacetamide model in mice. In: Lab Animals, 2015, 49 (S1), S. 21-9.

* Weiskirchen R, Mahli A, Weiskirchen S, Hellerbrand C. The hop constituent xanthohumol exhibits hepatoprotective effects and inhibits the activation of hepatic stellate cells at different levels. In: In: Front Physiol, 2015, 6:140.

* Weiskirchen R, Uerlings R. Laser ablation inductively coupled plasma mass spectrometry in biomedicine and clinical diagnosis. In: Cell Mol Med: Open access, 2015, 1, 1:3.

* Weiskirchen R. Special issue on experimental models of liver injury in mice in Laboratory Animals. [Announcement] http://apasl.info/archives/2560

*Weiskirchen R, Tacke F. Small heterodimer partner (SHP) links hepatitis C and liver fibrosis: A small protein on the big stage. In: Liver Int, 2015, 35, S. 2218-21.

* Weiskirchen R: CCN1, a molecular switch that imposes a self-limiting control on inflammation and wound healing in a multitude of organs? In: Am J Physiol Lung Cell Mol Physiol 2015, 309, S. L747-L748.

* Weiskirchen R: Supplement to “Lipocalin-2 (LCN2) regulates PLIN5 expression and intracellular lipid droplet formation in the liver” In: World Biomed Front (Section Diabetes and Obesity) 2015, http://biomedfrontiers.org/diabetes-obesity-2015-9-9/

* Abnaof K, Mallela N, Vinold N, Walenda G, Meurer SK, Seré K, Lin Q, Smeets B, Hoffmann K, Wagner W, Zenke M, Weiskirchen R, Fröhlich H. TGF-beta stimulation in human in murine cells reveals commonly affected biological processes and pathways at transcriptional level. In: BMC Systems Biology, 2014, 8:55.

* Asimakopoulou A, Borkham-Kamphorst E, Henning M, Yagmur E, Gassler N, Berger T, Mak TW, Weiskirchen R. Lipocalin 2 (LCN2) regulates OXPAT expression and intracellular lipid droplet formation in the liver. In: BBA Mol Cell Biol Lipids, 2014, 1841, S. 1513-24.

* Boaru SG, Merle U, Uerlings R, Zimmermann A, Weiskirchen S, Stremmel W, Weiskirchen R. Simultaneous monitoring of cerebral metal accumulation in an experimental model of Wilson's disease by laser ablation inductively coupled plasma mass spectrometry. In: BMC Neuroscience, 2014, 15:98

* Borkham-Kamphorst E, Schaffrath C, van de Leur E, Haas U, Tihaa L, Weiskirchen R. The antifibrotic effects of CCN1/CYR61 in primary portal myofibroblasts are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF-β signaling. In: BBA Mol Cell Res, 2014, 1843, S. 902-14.

* Bultmann CA, Weiskirchen R. MAKERGAUL: An innovative MAK-based model and software for real-time PCR quantification. In: Clin Biochem 2014, 47, S. 117-22.

* Koch A, Zimmermann HW, Gassler N, Jochum C, Weiskirchen R, Bruensing J, Buendgens L, DückersH, Bruns T, Gerken G, Neumann UP, Adams DH, Trautwein C, Canbay A, Tacke F. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure. In: Liver Int, 2014, 34, S. 1330-9.

* Martinez-Palacian A, Kanse SM, Weiskirchen R. Factor seven activating proteiase (FSAP): a novel protective factor in liver fibrosis. In: Prot Clin Appl, 2014, 8, S. 438-46.

* Meurer SK, Alsamman M, Scholten D, Weiskirchen R. Endoglin in liver fibrogenesis -- Bridging basic science and clinical practice. In: World J Biol Chem, 2014, 5, S. 180-203.

* Schon HT, Weiskirchen R. Immunmodulatory effects of transforming growth factor-β in the liver. In: Hepatobiliary Surg Nutr, 2014, 3, S. 386-406.

Stöcker W, Karmilin K, Hildebrandt A, Westphal H, Yiallouros R, Weiskirchen R, Dietzel E, Floehr J, Jahnen-Dechent W. Mammalian gamete fusion depends on the inhibition of ovastacin by fetuin-B. In: Biol Chem, 2014, 395, S. 1195-9.

* Tacke F, Weiskirchen R. Liver immunology: new perspectives (Editorial). In: Hepatobiliary Surg Nutr, 2014, 3, S. 330.

* van Helden J, Weiskirchen R. Hepatitis C diagnostics: clinical evaluation of the HCV-core antigen determination (Hepatitis C Diagnostik: Klinische Evaluierung der HCV-core Antigen Bestimmung). In: Z. Gastroenterol., 2014, 52, S. 1164-70.

* Weiskirchen R, Tacke F. Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology. In: Hepatobiliary Surg Nutr, 2014, 3, S. 344-63.

* Winkler S, Borkham-Kamphorst E, Stock P, Brückner S, Weiskirchen R, Christ B. Human mesenchymal stem cells towards non-alcoholic steatohepatitis in an immunodeficient mouse model. In: Exp Cell Res, 2014, 326, S. 230-9.

* Borkham-Kamphorst E, Gassler N, Zimmermann HW, Bissels U, Bosio A, Tacke F, Weiskirchen R, Kanse SM. Factor VII activating protease (FSAP) exerts anti-inflammatory and anti-fibrotic effects in liver fibrosis in mice and men. In: J Hepatology, 2013, 58, S. 104-11.

* Borkham-Kamphorst E, van de Leur E, Zimmermann HW, Karlmark KR, Tihaa L, Haas U, Tacke F, Berger T, Mak TW, Weiskirchen R. Protective effects of Lipocalin-2 (LCN2) in acute and chronic liver injury suggesting a novel function in liver homeostasis. In: BBA Mol Bas Dis, 2013, 1832, S. 660-73.

* Cubero FJ; Singh A, Borkham-Kamphorst E, Nevzorova YA, Al Masaoudi M, Haas U, Boekschoten M, Gassler N, Weiskirchen R., Müller M, Liedtke C, Trautwein C. TNFR1 determines progression of chronic liver inury in the IKKgamma/Nemo genetic model. In: Cell Death & Differ 2013, 20, S. 1580-92.

* Dietzel E, Wessling J, Floehr J, Schäfer C, Enssler S, Denecke B, Rösing B, Neulen J, Veitinger T, Spehr M, Tropartz T, Tolba R, Renné T, Egert A, Schorle H, Gottenbusch Y, Hildebrand A, Yiallouros I, Stöcker W, Weiskirchen R, Jahnen-Dechent W. Fetuin-B, a liver-derived plasma protein is essential for fertilization. In: Dev Cell, 2013, 25, S. 106-12.

* Huss S, Stellmacher C, Goltz D, Khlistunova I, Adam AC, Tebicka J, Kirfel J, Büttner R, Weiskirchen R. Deficiency in four and one half LIM domain protein 2 (FHL2) aggravates liver fibrosis in mice. In: BMC Gastroenterol, 2013, S. 13:8.

* Koch A, Weiskirchen R, Kunze J, Dückers H, Bruensing J, Buendgens L, Matthes M, Luedde T, Trautwein C, Tacke F. Elevated asymmetric dimethylarginine levels predict short- and long-term mortality risk in critically ill patients. In: J Crit Care, 2013, 28, S. 947-53.

* Koch A, Weiskirchen R, Bruensing J, Dückers H, Buendgens, L, Kunze J, Matthes M, Luedde T, Trautwein C, Tacke F. Regulation and prognostic relevance of symmetric dimethylarginine serum concentrations in critical illness and sepsis. In: Med Inflamm, 2013, Article ID 413826.

* Labbus K, Henning M, Borkham-Kamphorst E, Geisler C, Berger T Mak TW, Knüchel R, Meyer HE, Weiskirchen, R. Henkel, C. Proteomic profiling in Lipocalin 2 deficient mice under normal and inflammatory conditions. In: J Proteomics, 2013, 78C, S. 188-96.

* Liedtke C, Luedde T, Sauerbruch T, Scholten D, Steetz K, Tacke F, Tolba R, Trautwein C,Trebicka J, Weiskirchen R. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects. In: Fibrogenesis & Tissue Rep 2013, 6:19.

* Martin IV, Borkham-Kamphorst E, Zok S, van Roeyen CRC, Eriksson U, Boor P, Hiththetiya K, Fischer HP, Wasmuth HE, Weiskirchen R, Eitner F, Floege J, Ostendorf T. Platelet-derived growth factor (PDGF)-C neutralization reveals differential roles of PDGF-receptors in liver and kidney fibrosis. In: Am J Pathol, 2013, 182, S. 107-17.

* Meurer SK, Alsamman M, Sahin H, Wasmuth HE, Kisseleva T, Brenner DA, Trautwein C, Weiskirchen R, Scholten D. Overexpression of Endoglin modulates ALK/Smad signalling pathways in a novel immortalized mouse hepatic stellate cell line. In: PLOS ONE, 2013, 8(2):e56116.

* M-M P, Weiskirchen R, Gassler N, Bovi M, Becker JS. Novel bioimaging techniques of metals by laser ablation inductively coupled plasma mass spectrometry for diagnosis of fibrotic and cirrhotic liver disorders. In: PLOS ONE, 2013, 8(3):e58702.

* M-M P, Merle U, Weiskirchen R, Becker JS. Bioimiaging of copper deposition in Wilson's disease mouse liver by laser ablation inductively coupled plasma mass spectrometry imaging (LA-ICP-MS). In: Int J Mass Spectrom, 2013, 354-355, S. 281-7.

* Roderburg C, Luedde M, Cardenas DV, Vucur M, Mollnow T, Zimmermann HW, Koch A, Hellerbrand C, Weiskirchen R, Frey N, Tacke F, Trautwein C, Luedde T. miR-133a mediates TGF-β-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. In: J Hepatology, 2013, 58, S. 736-42.

* Sahin H, Borkham-Kamphorst E, do O NT, Berres ML, Kaldenbach M, Schmitz P, Weiskirchen R, Liedtke C, Streetz K, Maedler K, Trautwein C, Wasmuth HE. Proapoptotic effects of the chemokine CXCL10 are mediated by the noncognate receptor TLR4 in hepatocytes. In: Hepatology, 2013, 57, S. 797-805.

* Walenda G, Abnaof K, Joussen S, Meurer SK, Smeets B, Rath B, Hoffmann K, Fröhlich H, Zenke M, Weiskirchen R, Wagner W. TGF-beta 1 does not induce senescence of mesenchymal stromal cells and has similar effects in early and late passages. In: PLOS ONE, 2013, 8(10):e77656.

* Weiskirchen R. Evaluation von Genpolymorphismen und Identifikation neuer diagnostischer Serummarker fibrosierender Lebererkrankungen. (Evaluation of gene polymorphisms and identification of novel diagnostic serum markers in liver fibrogenesis. In: Kompetenznetzwerk Hepatitis. 10 Jahre Kompetenznetz Hepatitis, 2013, S. 96-7.

* Weiskirchen R, Meurer SK. BMP-7 counteracting TGF-beta1 activities in organ fibrosis. In: Front Biosci, 2013, 18, S. 1435-44.

* Weiskirchen R, Weimer J, Meurer SK, Kron A, Seipel B, Vater I, Arnold N, Siebert R, Xu L, Friedman SL, Bergmann C. Genetic characteristics of the human hepatic stellate cell line LX-2. In: PLOS ONE, 2013, 8(10) e75692.

* Yagmur E, Weiskirchen R, Schedel A, Bugert P. PTGS1 compounds heterozygosity impairs gene expression and platelet aggregation and is associated with severe bleeding complications. In: Thromb & Haemost, 2013, 110, S. 1083-5.

* Bergmann C, Weiskirchen R. It's not all in the cilia, but on the road to it: Genetic interaction network in polycystic kidney and liver diseases and how trafficking and quality control matter. In: J Hepatology, 2012, 56, S. 1201-3.

* Boaru SG, Borkham-Kamphorst E, Tihaa L, Haas U, Weiskirchen R. Expression analysis of inflammasome components in experimental models of inflammatory and fibrotic liver disease. In: J Inflamm, 2012, 9(1):48.

* Borkham-Kamphorst E, van Roeyen CR, Floege J, Weiskirchen R. CCN3/NOV small interfering RNA enhances fibrogenic gene expression in hepatic stellate cells and cirrhotic fat storing cell line CFSC. In: J Cell Comm Signal, 2012, 6, S. 11-25.

* Borkham-Kamphorst E, Van de Leur E, Huss S, Haas U, Weiskirchen R. Adenoviral CCN3/NOV gene transfer induces apoptosis and inhibits epithelial-to-mesenchymal transition in hepatocytes in vitro but fails to attenuate liver fibrosis in an experimental bile duct ligation model because of hepatocyte apoptosis. In: Liver Int, 32, 2012, S. 1342-53.

* Jansen J, Rosenkranz E, Overbeck S, Warmuth S; Mocchegiani E, Giacconi R, Weiskirchen R, Karges W, Rink L. Disturbed zinc homeostasis in diabetic patients by in vitro and in vivo analysis of insulinomimetic activity of zinc. In: J Nutr Biochem, 2012, 23, S. 1458-66.

* Kabgani N, Grigoleit T, Schulte K, Sechi A, Sauer-Lehnen S, Tag C, Warsow G, Schordan S, Mostertz J, Homuth G, Endlich N, Tacke F, Weiskirchen R, Füllen G, Endlich K, Floege J, Smeets B, Moeller MJ. Primary cultures of primary parietal cells and podocytes with proven origin. In: PLoS ONE, 2012, 7:e34907.

* Meurer SK, Esser M, Tihaa L, Weiskirchen R. BMP-7/TGF-β1 signalling in myoblasts: Components involved in signalling and BMP-7-dependent blockage of TGF-β-mediated CTGF expression. In: Eur J Cell Biol, 2012, 91, S. 450-63.

* Nevzorova YA, Bangen JM, Weiskirchen R, Haas U, Hu W, Heymann F, Kroy D, Gassler N, Sicinski P, Tacke F, Trautwein C, Liedtke C. Cyclin E1 controls proliferation of hepatic stellate cells and is essential for liver fibrogenesis in mice. In: Hepatology, 56, 2012, S. 1140-9.

* Oezdemir RF, Gaisa NT, Lindemann-Docter K, Weiskirchen R, Ahrens M, Schwamborn K, Stephan C, Pfister D, Heidenreich A, Knuechel R, Henkel C. Proteomic tissue profiling for improvement of grading of noninvasive papillary urothelial neoplasia. In: Clin Biochem, 45, 2012, S. 7-11.

* Parahuleva, M. S., Hölschermann, H., Zandt, D., Pons-Kühnemann, J., Behnoush, P., Weiskirchen, R., Staublitz, A., Tillmanns, H., Erdogan, A., Kanse, S. Circualting Factor VII activating protease (FSAP) is associated with clinical outcome in acute coronary syndrome. In: Circulation J, 2012, 76, S. 2853-61.

* Reichenbach V, Fernandez-Varo G, Casals G, Oro D, Ros J, Melgar-Lesmes P, Weiskirchen R, Morales-Ruiz M, Jimenez W. Adenoviral dominant-negative soluble PDGFRbeta improves hepatic collagen, systemic hemodynamics, and portal pressure and fibrosis in fibrotic rats. In: J Hepatology, 2012, 57, S. 967-73.

* Sahin H, Borkham-Kamphorst E, Kuppe C, Zaldivar MM, Grouls C, Al-samman M, Nellen A, Schmitz P, Heinrichts D, Berres ML, Doleschel D, Scholten D, Weiskirchen R, Moeller MJ, Kiessling F, Trautwein C, Wasmuth HE. The chemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice. In: Hepatology, 2012, 55, S. 1610-9.

* Seidler A, Zimmermann HW, Weiskirchen R, Trautwein C, Tacke F. Elevated circulating soluble interleukin-2 receptor in patients with chronic liver diseases is associated with non-classical monocytes. In: BMC Gastroenterol, 2012, 12:38.

* Tacke F, Weiskirchen, R. Update on hepatic stellate cells - pathogenic role in liver fibrosis and novel isolation techniques. In: Exp Rev Gastroenterol Hepatol 6, 2012, S. 67-80.

* van Roeyen CR, Boor P, Borkham-Kamphorst E, Rong S, Kunter U, Martin IV, Kaltovic A,, Fleckenstein S, Perbal B, Trautwein C, Weiskirchen R, Ostendorf T, Floege J. A novel, dual role of CCN3 in experimental glomerulonephritis: pro-angiogenic and anti-mesangioproliferative effects. In: Am J Pathol, 180, 2012, S. 1979-90.

* Borkham-Kamphorst E, Drews F, Weiskirchen R. Induction of LCN2 expression in acute and chronic experimental liver injury moderated by proinflammatory cytkines IL-1β throgh NF-kB activation. In: Liver Int, 31, 2011, S. 656-65.

* Hellerbrand C, Weiskirchen R. Does it not only matter how much but also when we eat to induce fatty liver? In: Hepatology 54, 2011, S. 1096-99.

* Henkel C, Schwamborn K, Zimmermann HW, Tacke F, Kühnen E, Odenthal M, Groseclose MR, Caprioli RM, Weiskirchen R. From multimarker profiling to interesting proteins: Thymosin-β4 and Kininogen-1 as new biomarkers for inflammatory hepatic disease. In: J Cell Mol Med 15, 2011, S. 2176-88.

* Kämmerer, E., Peuscher, A., Reinartz, A., Liedtke, C., Weiskirchen, R., Kopitz, J., Gassler, N. Human acyl-CoA synthetase 5 is sensitive to the inhibitor triascin C. In: World J Gastroenterol 17, 2011, S. 4883-9.

* Meurer SK, Tihaa L, Borkham-Kamphorst E, Weiskirchen R. Expression and functional analysis of endoglin in isolated liver cells and its involvement in fibrogenic Smad signalling. In: Cell Signal 23, 2011, S. 683-99.

* Pieper-Fürst, U., Hall, R., Huss, S., Fischer, H.-P., Tacke, F., Weiskirchen, R., Hochrath, K., Lammert, F. Expression of the megalin C-terminal fragment by macrophages during liver fibrogenesis in mice. In: BBA Mol Bas Dis, 2011, S. 1640-8.

* Rauen T, Weiskirchen R, Floege, J. In search of early events in the development of chronic kidney disease: The emerging role for lipocalin-2/NGAL In: Nephrol Dial Transplant 26, 2011, S. 445-7.

* Scholten D, Weiskirchen R. Questioning the challenging role of epithelial-to-mesenchymal transition in liver injury. In: Hepatology 53, 2011, S. 1048-51.

* Weiskirchen R. CCN proteins in liver health and disease. In: Front Biosci 16, 2011, S. 1939-61.

* Berres ML, Koenen RR, Rueland A, Zaldivar MM, Heinrichs D, Sahin H, Schmitz P, Streetz KL, Gassler N, Weiskirchen R, Proudfoot A, Weber C, Trautwein C, Wasmuth HE. Antagonism of the chemokine CCL5 (RANTES) ameliorates experimental liver fibrosis in vivo. In: J Clin Invest 120, 2010, S. 4129-40.

* Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F, Weber A, Weiskirchen R, Liedtke C, Gassler N, Müller M, de Vos R, Wolf MJ, Boege YT, Seleznik GM, Zeller N, Erny D, Fuchs T, Zoller S, Cairo S, Buendia MA, Prinz M, Akina S, Tacke F, Heikenwalder M, Trautwein C, Luedde. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. In: Cancer Cell 17, 2010, S. 481-96.

* Bohr W, Kupper M, Hoffmann K, Weiskirchen R. Recombinant expression, purification, and functional characterization of Connective Tissue Growth Factor and Nephroblastoma-Overexpressed Protein. In: PLoS ONE, 2010, 5 (12): e160000.

* Bomble M, Tacke F, Rink L, Kovalenko E, Weiskirchen R. Analysis of antigen-presenting funtionality of cultured rat hepatic stellate cells and transdifferentiated myofibroblasts. In: Biochem Biophys Res Comm 396, 2010, S. 342-7.

* Huss S, Schmitz J, Goltz D, Fischer H-P, Büttner R, Weiskirchen R. Development and evaluation of an open source Delphi-based software for morphometric quantification of liver fibrosis. In: BMC Fibrogenesis & Tissue Repair, 2010, S. 3:10.

* Kaemmerer E, Plum P, Klaus C, Weiskirchen R, Schippers A, Wagner N, Reinartz A, Gassler N. Fatty acid binding receptors in intestinal physiology and pathophysiology. In: Word J Gastrointest Pathophysiol 15, 2010, 147-53.

* Koch A, Weiskirchen R, Zimmermann HW, Sanson E, Trautwein C, Tacke F. Relevance of serum leptin and leptin-receptor concentrations in critically ill patients. In: Mediat Inflamm, 2010, pi: 473540.

* Koch A, Weiskirchen R, Sanson E, Zimmermann HW, Voigt S, Dückers H, Trautwein C, Tacke F. Circulating Retinol-Binding-Protein 4 concentrations in critically ill patients before specific treatment: prognostic impact and correlation with organ function, metabolism and inflammation. In: Crit Care 14, 2010, R179.

* Kovalenko E, Weiskirchen R. Diagnostischer Wert der Serum CTGF/CCN2 Konzentrationen und einzelner CTGF-Genpolymorphismen bei fibrotischen Lebererkrankungen: Erkenntnisse aus einem geförderten Projekt der Stiftung für Pathobiochemie und Molekularen Diagnostik der Deutschen Vereinten Gesellschaft für Klinische Chemie und Pathobiochemie. In: Klin Chem Mitteilungen 41, 2010, S. 32-47.

* Parahuleva MS, Hölschermann H, Erdogan A, Langanke E, Prickartz I, Parviz B, Weiskirchen R, Tillmanns H, Kanse S. Factor seven activating protease (FSAP) levels during normal pregnancy and in women using oral contraceptives. In: Thrombosis Res 126, 2010, S. 36-40.

* Reinartz A, Ehling J, Leue A, Liedtke C, Schneider U, Kopitz J, Weiss T, Hellerbrand C, Weiskirchen R, Knüchel R, Gassler N. Lipid-induced upregulation of human acyl-CoA synthetase 5 promotes hepatocellular apoptosis . In: Biochim Biophys Acta 1801, 2010, S. 1025-35.

* Schoenherr C, Weiskirchen R, Haan S. Interleukin-27 acts on hepatic stellate cells and induces signal transducer and activator of transcription-1-dependent responses. In: Cell Commun & Signal, 2010, 6:19.

* Tacke F, Weiskirchen R. Pathophysiologie der Leberfibrose: Aktuelle Aspekte und neue Ansätze für antifibrotische Therapien (Liver fibrosis - pathogenesis and novel therapeutic approaches). In: Internist 51, 2010, S. 21-9.

* Wasmuth HE, Weiskirchen R. Pathogenese der Leberfibrose: Regulation von Sternzellen durch Chemokine (Pathogenesis of liver fibrosis: Modulation of stellate cells by chemokines). In: Z Gastroenterol 48, 2010, S. 38-45.

* Wasmuth HE, Weiskirchen R. Personlized medicine in hepatitis C: From genome wide association studies to clinical practice. In: Hepatology 51, 2010, S. 2223-5.

* Zaldivar MM, Pauels K, von Hundelshausen P, Berres ML, Schmitz P, Bornemann J, Kowalska MA, Gassler N, Weiskirchen R, Trautwein C, Weber C, Wasmuth HE. The chemokine CXCL4 (PF4) is a platelet-derived mediator of HCV-induced and experimental liver fibrosis. In: Hepatology 51, 2010, S. 1345-53.

* Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C, Zernecke A, Tischendorf JJ, Luedde T, Weiskirchen R, Trautwein C, Tacke F. Functional contribution of elevated circulating and hepatic non-classical CD14+CD16+ monocytes to inflammation and human liver fibrosis. In: PLoS ONE 5, 2010, e1049.

* Bender H, Wiesinger MY, Nordhoff C, Schoenherr C, Ludwig S, Weiskirchen R, Kato N, Heinrich PC, Haan S. Interleukin-27 displays interferon γ-like functions in human hepatoma cells and hepatocytes. In: Hepatology 50, 2009, S. 585-91.

* Berres ML, Papen S, Pauels K, Schmitz P, Moreno Zaldivar M, Hellerbrand C, Müller T, Berg T, Weiskirchen R, Trautwein C, Wasmuth HE. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. In: J Hepatol 50, 2009, S. 370-6.

* Gressner OA, Lahme B, Weiskirchen R, Gressner AM. Connective tissue growth factor is a Smad2 regulated amplifier of transforming growth factor ß actions in hepatocytes - but without modulating bone morphogenetic protein 7. In: Hepatology 49, 2009, S. 2021-30.

* Karlmark, KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F, Weber C, Merad M, Luedde T, Trautwein C, Tacke F. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. In: Hepatology 50, 2009, S. 261-74.

* Kovalenko E, Tacke F, Gressner OA, Zimmermann H, Lahme B, Janetzko A, Wiederholt T, Berg T, Müller T, Trautwein C, Gressner AM, Weiskirchen R. Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as non-invasive biomarkers for the assessment of liver fibrosis. In: J Viral Hepatitis 16, 2009, S. 612-20.

* Mohren S, Weiskirchen R. Non-synonymous gene polymorphisms in the secretory signal peptide of human TGF-ß1 affect cellular synthesis but not secretion of TGF-ß1. In: Biochem Biophys Res Commun 379, 2009, S. 1015-20.

* Nevzorova YA, Tschaharganeh D, Gassler N, Weiskirchen R, Sicinski P, Trautwein C, Liedtke C. Aberrant cell cycle progression and endoreplication in regenerating livers of mice that lack a single E-type cyclin. In: Gastroenterology, 137, 2009, S. 691-703.

* Roderfeld M, Weiskirchen R, Atanasova S, Gressner AM, Preissner KT, Roeb E, Kanse SM. Altered factor VII activating protease expression in murine hepatic fibrosis and its influence on hepatic stellate cells. In: Liver Int 29, 2009, S. 686-91.

* Schwamborn K, Krieg, RC, Grosse J, Reulen N, Weiskirchen R, Knuechel R, Jakse G, Henkel C. Serum proteomic profiling in patients with bladder cancer. In: Eur Urol 56, 2009, S. 989-97.

* von Oppen N, Schurich A, Hegenbarth S, Stabenow D, Tolba R, Weiskirchen R, Geerts A, Kolanus W, Knolle P, Diehl L. Systemic antigen cross-presented by liver sinusoidal endothelial cells induces liverspecific CD8 T cell retention and tolerization. In: Hepatology 49, 2009, S. 1664-72.

* Wasmuth HE, Tag CG, Van de Leur E, Hellerbrand C, Mueller T, Berg T, Puhl G, Neuhaus P, Samuel D, Trautwein C, Kanse SM, Weiskirchen R. The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB. In: Hepatology 49, 2009, S. 775-80.

* Wasmuth HE, Lammert F, Moreno Zaldivar M, Weiskirchen R, Scholten D, Hellerbrand C, Berres ML, Tacke F, Hillebrandt S, Wiederholt T, Schmitz P, Keppeler H, Berg T, Dahl E, Gassler N, Friedman SL, Trautwein, C. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. In: Gastroenterology 137, 2009, S. 309-19.

* Weiskirchen R, Wasmuth HE. The genes that underlie fatty liver disease: the harvest has begun. In: Hepatology 49, 2009, S. 692-4.

* Weiskirchen R, Meurer SK, Gressner OA, Herrmann J, Borkham-Kamphorst E, Gressner AM. BMP-7 as antagonist of organ fibrosis. In: Front Biosci 14, 2009, S. 4992-5012.

* Weiskirchen R, Liedtke C, Trautwein C. When Sleeping Beauty wakes up and jumps into cancer-minded environment. In: Hepatology 49, S. 2122-4.

* Borkham-Kamphorst E, Kovalenko E, van Roeyen CRC, Gassler, N., Bomble M, Ostendorf T, Floege J, Gressner AM, Weiskirchen R. Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury. In: Lab Invest 88, 2008, S. 1090-100.

* Drews F, Knöbel S, Moser M, Muhlack KG, Mohren S, Stoll C, Bosio A, Gressner AM, Weiskirchen R. Disruption of the latent transforming growth factor-ß binding protein-1 gene causes alteration in facial structure and influences TGF-ß bioavailability. In: BBA Mol Cell Res 1783, 2008, S. 34-48.

* Gressner OA, Lahme B, Rehbein K, Siluschek M, Weiskirchen R, Gressner AM. Pharmacological application of caffeine inhibits TGF-ß-stimulated connective tissue growth factor expression in hepatocytes via PPARgamma and SMAD2/3-dependent pathways. In: J Hepatol 49, 2008, 49, S. 758-67.

* Gressner, O. A., Lahme, B., Siluschek, M., Rehbein, K., Weiskirchen, R., Gressner, A. M. Intracrine signalling of activin A in hepatocytes upregulates connective tissue growth factor (CTGF/CCN2) expression. In: Liver Int. 28, 2008, S. 1207-16.

* Gressner OA, Lahme B, Siluschek M, Rehbein K, Herrmann J, Weiskirchen R, Gressner AM. Activation of TGF-ß in cultured hepatocytes and during liver injury leads to intracrine signaling with expression of connective tissue growth factor (CTGF/CCN2). In: J Cell Mol Med 12, 2008, S. 2717-30.

* Gressner OA, Rizk MS, Kovalenko E, Weiskirchen, R., Gressner AM. Changing the pathogenetic roadmap of liver fibrosis. Where did it start -- where will it go? In: J Gastroenterol Hepatol 23, 2008, S. 1024-35.

* Muetze S, Leeners B, Ortlepp JR, Kuse S, Tag CG, Weiskirchen R, Gressner AM, Rudnik-Schoeneborn S, Zerres K, Rath W. Maternal Factor V Leiden mutation is associated with HELLP syndrome in Caucasian women. In: Acta Obstet Gyn Scan 87, 2008, S. 635-42.

* Sagave JF, Moser M, Ehler E, Weiskirchen S, Stoll D, Günter K, Büttner R, Weiskirchen R. Targeted disruption of the mouse Csrp2 gene encoding the cysteine- and glycine-rich LIM domain protein CRP2 result in subtle alteration of cardiac ultrastructure. In: BMC Dev Biol, 2008, 8:80.

* Salguero Palacios R, Roderfeld M, Hemmann S, Rath T, Srebrena A, Tschuschner A, Gressner OA, Weiskirchen R, Graf J, Roeb E. Activation of hepatic stellate cells is associated with cytokine expression in thioacetamide induced hepatic fibrosis in mice. In: Lab Invest 88, 2008, S. 1192-203.

* Tacke F, Weiskirchen R, Trautwein C. Liver function critically determines serum retinol-binding protein 4 (RBP4) levels in patients with chronic liver disease and cirrhosis. In: Hepatology 48, 2008, S. 1724-5.

* Tag CG, Oberkanins C, Ingram CJE, Swallow DM, Gressner AM, Weiskirchen R. Establishment and evaluation of a novel reverse-hybridization teststrip covering Single-Nucleotide Polymorphisms that are associated with adult-type hypolactasia. In: Clin Chim Acta 392, 2008, S. 58-62.

* Tag CG, Gressner AM, Weiskirchen R. Rapid FSAP genotyping of the E393Q (Marburg II) and G534E (Marburg I) polymorphisms on the LightCycler in a multiplex PCR using two fluorescently labeled probe sets. In: The Open Clin Chem J 1, 2008, S. 42-6.

* Wang H, Zhao YP, Gao CF, Jl Q, Gressner AM, Yang ZX, Weiskirchen R. Transforming growth factor ß1 gene variants increase transcription and are associated with liver cirrhosis in Chinese. In: Cytokine 43, 2008, 20-5.

* Wasmuth HE, Moreno Zaldivar M, Berres ML, Werth A, Scholten D, Hillebrandt S, Tacke F, Schmitz P, Dahl E, Wiederholt T, Hellerbrand C, Berg T, Weiskirchen R, Trautwein C, Lammert F. The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. In: J Hepatol 48, 2008, S. 208-15.

* Weiskirchen R, Borkham-Kamphorst E, Meurer SK, Drews F, Mohren S, Herrmann J, Gressner OA, Scherner O, Vreden WN, Kovalenko E, Bomble M, Gressner AM. A complex network of intra- and intercellular mediators regulate cellular activation and transdifferentiation of hepatic stellate cells. J. Bosch, A. K. Burroughs, F. Lammert, D. Lebrec, T. Sauerbruch (eds). Springer Verlag, Heidelberg, Germany, 2008, S. 45-69. ISBN: 978-1-4020-8655-7

* Weiskirchen R, Lammert F. A yellow bullet against the drivers of hepatic fibrogenesis. In: Hepatology 48, 2008, S. 683-5. 

* Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, Floege J, Gressner AM, Weiskirchen R. Pro-fibrogenic potential of PDGF-D in liver fibrosis. In: J Hepatol 46, 2007, S. 1064-74.

* Gressner OA, Lahme B, Demirci I, Gressner AM, Weiskirchen R. Differential effects of TGF-ß on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. In: J Hepatol 47, 2007, S. 699-710.

* Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: Clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. In: Clin Chim Acta 381, 2007, S. 107-13.

* Gressner, OA, Weiskirchen R, Gressner AM. Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. In: Comp Hepatol 2007, 6:7.

* Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrogenesis, and genetic pre-disposition pending between fiction and reality. In: J Cell Mol Med 11, S. 1031-51.

* Gressner, OA, Weiskirchen R, Gressner AM. Neue pathogenetische Konzepte der Leberfibrose mit Optionen für Therapie und Diagnostik (New pathogenetic concepts of liver fibrosis with options for therapy and diagnostics). In: Med Welt 58, S. 613-20.

* Herrmann J, Gressner AM, Weiskirchen R. Immortal hepatic stellate cell lines: useful tools to study hepatic stellate cell biology and function? In: J Cell Mol Med 11, S. 704-22.

* Herrmann J, Haas U, Gressner AM, Weiskirchen R. TGF-ß up-regulates serum response factor in activated hepatic stellate cells. In: BBA Mol Bas Dis 1772, 1250-7.

* Scherner O, Meurer SK. Tihaa L, Gressner AM, Weiskirchen R. Endoglin differentially modulates antagonistic TGF-ß and BMP-7 signaling. In: J Biol Chem 282, 2007, S. 13934-43.

* Tag CG, Schifflers MC, Mohnen M, Gressner AM, Weiskirchen R. A novel proximal - 13914G>A base replacement in the vicinity of the common-13910T/C lactase gene variation results in an atypical LightCycler melting curve in testing with the MutaREAL lactase test. In: Clin Chem 53, 2007, S. 146-8.

* Tag CG, Mengsteab S, Kanse SM, Weiskirchen R. Rapid genotyping of the G534E polymorphism (Marburg I) of the gene encoding the factor VII-activating protease (FSAP) by LightCycler PCR [Letter]. In: Clin Biochem 40, 2007, S. 1063-4.

* Weiskirchen R, Tag CG, Mengsteab S, Gressner AM, Ingram CJE, Swallow DM. Pitfalls in LightCycler diagnosis of the Single-Nucleotide Polymorphism 13.9kb upstream of the Lactase gene that is associated with adult-type hypolactasia . In: Clin Chim Acta 384, 2007, S. 93-8.

* Weiskirchen R, Meurer S. BMP-7 in focus: A member of the transforming growth factor-ß superfamily is implicated in the maintenance of liver health . In: Hepatology 45, 2007, S. 1324-5.

* Winau F, Hegasy G, Weiskirchen R, Weber S, Cassan C, Sieling PA, Modlin RL, Liblau RS, Gressner AM, Kaufmann SH. lto cells are liver-resident antigen-presenting cells for activating T cell responses. In: Immunity 26, 2007, S. 117-29.

* Yagmur E, Weiskirchen R, Gressner AM, Trautwein C, Tacke F. Insulin resistance in liver cirrhosis is not associated with circulating Retinol Binding Protein 4. In: Diabetes Care 30, 2007, S. 1168-72.

* Antoine M, Mavituna M, Weiskirchen R, Gressner AM, Kiefer P. Plasma TGF-ß as a diagnostic and prognostic marker. In: Liver Diseases: Biochemical Mechanisms and New Therapeutic Insights (Shakir Ali, Scott L. Friedman, Derek A. Mann, eds.) Science Publishers Enfield, Yersey, Plymouth 2006, Vol. 2, S. 511-18.

* Bandapalli OR, Geheeb M, Kobelt D, Kühnle K, Elezkurtaj S, Herrmann J, Gressner AM, Weiskirchen R, Beule D, Blüthgen N, Herzel HP, Franke C, Brand K. Global analysis of host tissue gene expression in the invasive front of colorectal liver metastases. In: Int J Cancer 118, 2006, S. 74-89.

* Blondin D, Donner A, Gressner AM, Weiskirchen R. Diagnostische Methoden. In: Hämochromatosen - Hämosiderosen. Hrsg. A. Erhardt und D. Häussinger. UNI-MED Verlag AG, Bremen, London, Boston, 2006, S. 55-72. ISBN 3-89599-942-3.

* Erhardt A, Gressner AM, Weiskirchen R. Genetische Defekte und Pathogenese der hereditären Hämochromatose. In: Hämochromatosen - Hämosiderosen. Hrsg. A. Erhardt und D. Häussinger. UNI-MED Verlag AG, Bremen, London, Boston, 2006, S. 45-54. ISBN 3-89599-942-3.

* Frank J, Poblete-Gutiérrez P, Weiskirchen R, Gressner O, Merk HF, Lammert L. Hemochromatosis gene sequence deviations in german patients with porphyria cutanea tarda. In: Physiol Res. 2006, 55, S75-S83.

* Gressner AM, Lahme B, Meurer SK, Gressner O, Weiskirchen R. Variable expression of cystatin C in cultured transdifferentiating rat hepatic stellate cells. In: World J Gastroenterol 12, 2006, S. 731-38.

* Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-ß as major players and therapeutic targets. In: J Cell Mol Med 10, 2006, S. 76-99.

* Henkel C, Roderfeld M, Weiskirchen R, Berres ML, Hillebrandt S, Lammert F, Meyer HE, Stuehler K, Matern S, Roeb E. Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis. In: Proteomics 6, 2006, S. 6538-48

* Herrmann J, Borkham-Kamphorst E, Haas U, Van de Leur E, Fraga MF, Esteller M, Gressner AM, Weiskirchen R. The expression of CSRP2 encoding the Lim domain protein CRP2 is mediated by TGF-ß in smooth muscle and hepatic stellate cells. In: Biochem Biophys Res Commun 345, 2006, S. 1526-35.

* Kruit A, Grutters JC, Ruven HJT, van Moorsel CHM, Weiskirchen R, Mengsteab S, van den Bosch JMM. TGF-ß gene polymorphisms in Sarcoidosis patients with and without fibrosis. In: CHEST 129, 2006, S. 1584-91.

* Neyzen S, Van de Leur E, Borkham-Kamphorst E, Herrmann J, Hollweg G, Gressner AM, Weiskirchen R. Cryopreservation of hepatic stellate cells. In: J Hepat 44, 2006, S. 910-17.

* Roderfeld M, Weiskirchen R, Wagner S, Berres ML, Henkel C, Groetzinger J, Gressner AM, Matern S, Roeb E. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. In: FASEB J. 20, 2006, S. 444-54.

* Wang, H., Yang, Z. X., Gao, F., Xu, L. L., Tu X. Q., Zhao W. J., Kong, X. T., Gressner, A. M., Weiskirchen, R. The association of transforming growth factor-ß1 and its gene polymorphismus with multiple myeloma. In: Chin J Immunol 22, 2006, S. 650-6.

* Borkham-Kamphorst E, Meurer SK, Gressner AM, Weiskirchen R. Disruption of intermolecular disulfide bonds in PDGF-BB dimers by N-acetyl-L-cysteine does not prevent PDGF signaling in cultured hepatic stellate cells. In: Biochem Biophys Res Commun 338, 2005, S. 1711-8.

* Geier A, Gartung C, Theuri I, Zoller H, Weiss G, Lammert F, Dietrich CG, Weiskirchen R, Matern S. Occult celiac disease prevents the penetrance of hemochromatosis. In: World J Gastroenterol 11, 2005, S. 3323-6.

* Gressner AM, Dooley S, Weiskirchen R. TGF-ß and the Smad-pathway in liver fibrogenesis. In: Handbook of Fibrosis. J.-F. Dufour, P.-A. Clavien (eds). Springer Verlag, Heidelberg, Germany, 2005, S. 139-50.

* Gressner AM, Weiskirchen R. Neue molekulare Strategien zur Therapie von Lebererkrankungen: Viel versprechende Ansätze zur Behandlung der Leberfibrose. In: RWTH themen 2005/2 "Molecular Science for Life", S. 12-13.

* Henkel C, Roderfeld M, Weiskirchen R, Scheibe B, Matern S, Roeb E. Identification of fibrosis-relevant proteins using DIGE (Difference in Gel Electrophoresis) in different models of hepatic fibrosis. In: Z Gastroenterol 43, 2005, S.23-9.

* Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A, Schirin-Sokhan R, Wilkens G, Geier A, Lorenzen J, Köhl J, Gressner AM, Matern S, Lammert F. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. In: Nature Genetics 37, 2005, S. 835-43.

* Meurer S, Lahme B, Tihaa L, Weiskirchen R, Gressner AM. N-acetyl-L-cysteine suppresses TGF-ß signaling at distinct molecular steps: the biochemical and biological efficancy of a multifunctional, antifibrotic drug. In: Biochem Pharmacol 70, 2005, S. 1026-34.

* Meurer SK, Tihaa L, Lahme B, Gressner AM, Weiskirchen R. Identification of endoglin in rat hepatic stellate cells: new insights into TGF-ß receptor signaling. In: J Biol Chem 280, 2005, S. 3078-87.

* Poser I, Rothhammer T, Dooley S, Weiskirchen R, Bosserhoff AK. Characterisation of Sno expression in malignant melanoma. In: Int J Oncol 26, 2005, S. 1411-7.

* Tag CG, Schifflers MC, Mohnen M, Gressner AM, Weiskirchen R. Atypical melting curve resulting from genetic variation in the 3' untranslated region at position 20218 in the prothrombin gene analyzed with the lightcycler factor II (prothrombin) G20210A assay [Letter]. In: Clin Chem 51, 2005, S. 1560-1.

* Wang H, Mengsteab S, Tag CG, Gao CF, Hellerbrand C, Lammert F, Gressner AM, Weiskirchen R. Transforming growth factor-ß1 gene polymorphismus are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. In: World J Gastroenterol.11, 2005, S. 1929-36.

* Weiskirchen R, Gressner AM. Isolation and culture of hepatic stellate cells. In: Fibrosis Research Methods, (J Varga, DA Brenner, and SH Phan (eds)). Humana Press, Totowa, NJ, USA, 2005, S. 99-113.

* Borkham-Kamphorst E, Herrmann J, Stoll D, Treptau J, Gressner AM, Weiskirchen R. Dominant-negative soluble PDGF-ß receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. In: Lab Invest 84, 2004, S. 766-77.

* Borkham-Kamphorst E, Stoll D, Gressner AM, Weiskirchen R. Inhibitory effect of soluble PDGF-ß receptor in culture-activated hepatic stellate cells. In: Biochem Biophys Res Commun 317, 2004, S. 451-62.

* Borkham-Kamphorst E, Stoll D, Gressner AM, Weiskirchen R. Antisense strategy against PDGF ß-chain proves effective in preventing experimental liver fibrogenesis. In: Biochem Biophys Res Commun 321, 2004, S. 413-23

* Geier A, Reugels M, Weiskirchen R, Wasmuth HE, Dietrich CG, Gartung C, Lorenzen J, Bosserhoff AK, Brügmann M, Gressner AM, Matern S, Lammert F. Common heterozygous hemochromatosis gene mutations are genetic risk factors for disease progression in German patients with chronic hepatitis C. In: Liver Int 24, 2004, S. 285-94.

* Herrmann J, Abriss B, van de Leur E, Weiskirchen S, Gressner AM, Weiskirchen R. Comparative analysis of adenoviral transgene delivery via tail or portal vein into rat liver. In: Arch Virol 149, 2004, 1611-17.

* Herrmann J, Arias M, Van de Leur E, Gressner AM, Weiskirchen R. CSRP2, TIMP-1 and SM22 alpha promoter fragments direct hepatic stellate cell-specific transgene expression in vitro, but not in vivo. In: Liver Int 24, 2004, S. 69-79.

* Janoschek N, van de Leur E, Gressner AM, Weiskirchen R. Induction of cell death in activated hepatic stellate cells by target gene expression of the thymidine kinase/Ganciclovir system. In: Biochem Biophys Res Commun 316, 2004, S. 1107-15.

* Stoll C, Mengsteab S, Stoll D, Riediger D, Gressner AM, Weiskirchen R. Analysis of polymorphic TGFB1 codons 10, 25, and 263 in a german patient group with non-syndromic cleft lip, alveolus, and palate compared with healthy adults. In: BMC Med Genet 5, 2004, S. 1-9.

* Wang H, Yang ZX, Gao CF, Wan MB, Wang XJ, Mengsteab S, Gressner AM, Weiskirchen R. Transforming growth factor-ß1 gene polymorphisms in Caucasians and Asians with post hepatitis fibrosis. Acad J Sec Mil Med Univ 2004, 25, S. 1284-1287. 

* Abriss B, Hollweg G, Gressner AM, Weiskirchen R. Adenoviral-mediated transfer of p53 or retinoblastoma protein blocks cell proliferation and induces apoptosis in culture activated hepatic stellate cells. In: J. Hepatol. 38, 2003, S. 169-78.

*Arias M, Sauer-Lehnen S, Treptau J, Janoschek N, Theuerkauf I, Buettner R, Gressner AM, Weiskirchen R. Expression of a transforming growth factor-ß1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats. In: BMC Gastroenterology 3, 2003, 29.

* Gressner AM, Weiskirchen R, Dooley S. TGF-beta signaling in transdifferentiating hepatic stellate cells. In: Cell adhesion molecules in health and disease. Eds. Reutter W, Schuppan D, Tauber R, and Zeitz M. Kluwer Academic Publishers. Dordrecht. The Netherlands, 2003, S. 61-76.

* Gressner AM, Weiskirchen R. The tightrope of therapeutic suppression of active TGF-ß: High enough to fall deeply? [Editorial] In: J. Hepatol. 39, 2003, S. 858-61.

* Günther K, Stoll D, Jakse G, Gressner AM, Weiskirchen R. Rapid detection of CSRP2 mRNA in mouse, rat and human using LightCycler based quantitative real-time polymerase chain reaction. In: Anal Biochem 314, 2003, S. 144-48.

* Tag CG, Mengsteab S, Hellerbrand C, Lammert F, Gressner AM, Weiskirchen R. Analysis of the transforming-growth factor-ß1 (TGF-ß1) codon 25 gene polymorphism by LightCycler-analysis in patients with hepatitis C infection. In: Cytokine 24, 2003, S. 173-81.

* Weiskirchen R, Günther K. The CRP/MLP/TLP family of LIM domain proteins: acting by connecting. In: Bioessays 25, 2003, S. 152-62.

* Weiskirchen R, Moser M, Günther K, Weiskirchen S, Gressner AM. The murine latent TGF-beta binding protein (Ltbp-1) is alternatively spliced and maps to a region syntenic to human chromosome 2p21-22. In: Gene 308, 2003, S. 43-52.

* Arias M, Lahme B, Van de Leur E, Gressner AM, Weiskirchen R. Adenoviral delivery of an antisense RNA complementary to the 3'coding sequence of TGF-ß1 inhibits fibrogenic activities of hepatic stellate cells In: Cell Growth Differ 13, 2002, S. 265-73.

* Van de Leur E, Günther K, Gressner AM, Weiskirchen R. Increasing the biological safety during intravenous injection into mice tail vein using a modified plastic syringe (Letter). In: Baltic J. Lab. Anim. Sci. 12, S. 248-49.

* Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. In: Front Biosci 7, 2002, S. 793-807.

* Van de Leur E, Günther K, Gressner AM, Weiskirchen R. Increasing the biological safety during intravenous injection into mice tail vein using a modified plastic syringe. In: Baltic J. Lab. Anim. Sci. 12, S. 248-49.

* Weiskirchen R, Abriss B, Arias M, Kneifel J, Van de Leur E, Weiskirchen S, Gressner AM. Experimental approaches to antifibrotic strategies using gene transfer. In: A. M. Gressner, P. C. Heinrich, S. Matern (Hrsg.) Progress in Gastroenterology and Hepatology: Cytokines in Liver Injury and Repair, S. 335-53. Kluwer Academic Publications, Dordrecht, The Netherlands, 2002.

* Fehrenbach H, Weiskirchen R, Kasper M, Gressner AM. Upregulated Expression of the Receptor for Advanced Glycation End Products (RAGE) in Cultured Rat Hepatic Stellate Cells during Transdifferentiation to Myofibroblasts In: Hepatology 34, 2001, S. 943-52.

* Gao CF, Kong XT, Gressner AM, Weiskirchen R. The expression and antigenicity identification of recombinant rat TGF-ß1 in bacteria. In: Cell Research 11, 2001, S. 95-100.

* Tag CG, Gressner AM, Weiskirchen R. An unusual melting curve profile in LightCycler multiplex genotyping of the hemochromatosis H63D/C282Y gene mutations. In: Clin Biochem 34, 2001, S. 511-5.

* Weiskirchen R Congress Short Report Falk Symposium 125. In: Progress in Gastroenterology and Hepatology (Part II), Cytokines in Liver Injury and Repair. Falk Foundation, 2001, S. 1-42, ISBN: 3-933186-40-4.

* Weiskirchen R, Moser M, Weiskirchen S, Erdel M, Dahmen S, Buettner R, Gressner AM LIM-domain protein cysteine- and glycine-rich protein 2 (CRP2) is a novel marker of hepatic stellate cells and binding partner of the protein inhibitor of activated STAT1. In: Biochem J 259, 2001, S. 485-96.

* Weiskirchen R, Weiskirchen S, Gressner AM The hepatic stellate cell marker CRP2 is a cytokine sensitive LIM domain proteins with affinity for the protein inhibitor of activated STAT1 (PIAS1). In: E. Wisse, M. Arthur, R. B. de Zanger, D. L. Knock (Hrsg.) Cells of the hepatic sinusoid 8, 2001, S. 243-7.

* Weiskirchen R, Gressner AM. The Cysteine- and Glycine-Rich LIM Domain Protein CRP2 Specifically Interacts with a Novel Human Protein (CRP2BP) In: Biochem Biophys Res Comm 274, 2000, S. 655-63.

* Weiskirchen R, Kneifel J, Weiskirchen S, van de Leur E, Kunz D, Gressner AM Comparative evaluation of gene delivery devices in primary cultures of rat hepatic stellate cells and rat myofibroblasts In: BioMed Central Cell Biology 1:4, 2000, S. 1-9.

* Kloiber K, Weiskirchen R, Kräutler B, Bister K, Konrat R. Mutational analysis and NMR spectroscopy of quail cysteine and glycine-rich protein CRP2 reveal an intrinsic segmental flexibility of LIM domains In: J Mol Biol 92, 1999, S. 893-908.

* Oberst C, Hartl M, Weiskirchen R, Bister K. Conditional cell transformation by doxycycline-controlled expression of the MC29 v-myc allele In: Virol 53, 1999, S. 193-207.

* Erdel M, Weiskirchen R. Assignment of CSRP1 encoding the LIM domain protein CRP1 to human chromosome 1q32 by fluorescence in situ hybridization In: Cytogenet Cell Genet 83, 1998, S. 10-1.

* Konrat R, Kräutler B, Weiskirchen R, Bister K. Structure of cysteine and glycine-rich protein CRP2: backbone dynamics reveal motional freedom and independent spatial orientation of the LIM domains In: J Biol Chem 273, 1998, S. 23233-40.

* Konrat R, Weiskirchen R, Bister K, Kräutler B. Bispheric coordinative structuring in a zinc finger protein: NMR analysis of a point-mutant of the carboxy-terminal LIM domain of quail cysteine- and glycine-rich protein CRP2 In: J Am Chem Soc 120, 1998, S. 7127-28.

* Kontaxis G, Konrat R, Kräutler B, Weiskirchen R, Bister K. Structure and intramodular dynamics of the amino-terminal LIM domain from quail cysteine- and glycine-rich protein CRP2 In: Biochemistry 37, 1998, S. 7127-34.

* Konrat R, Weiskirchen R, Kräutler B, Bister K. Solution structure of the carboxyl-terminal LIM domain from quail cysteine-rich protein CRP2 In: J Biol Chem 272, 1997, S. 12001-7.

* Oberst C, Weiskirchen R, Hartl M, Bister K. Suppression in transformed avian fibroblasts of a gene (CO6) encoding a membrane protein related to mammalian potassium channel regulatory subunits In: Oncogene 14, 1997, S. 1109-16.

* Weiskirchen R, Erdel M, Utermann G, Bister K. Cloning, structural analysis and chromosomal localization of the human CSRP2 gene encoding the LIM domain protein CRP2 In: Genomics 44, 1997, S. 83-93.

* Mink S, Mutschler B, Weiskirchen R, Bister K, Klempnauer KH. A novel function for Myc: Inhibition of C/EBP-dependent gene activation In: Proc Natl Acad Sci USA 93, 1996, S. 6635-40.

* Weiskirchen R, Pino DJ, Macalma T, Bister K, Beckerle MC The cysteine-rich protein family of highly related LIM-domain proteins In: J Biol Chem 270, 1995, S. 28946-54.

* Bister K, Kerkhoff E, Siemeister G, Weiskirchen R Biochemistry of recombinant v-Myc proteins and differential gene expression in v-myc transformed cells In: W. Doerfler and P. Böhm (Hrsg.) Virus Strategies. VCH Publishers, Weinheim/New York, 1993.

* Weiskirchen R, Bister K Suppression in transformed avian fibroblasts of a gene (crp) encoding a cysteine-rich protein encoding LIM domains In: Oncogene 8, 1993, S. 2317-24.

* Weiskirchen R, Siemeister G, Hartl M, Bister K Sequence and expression of a glyceraldehyde-3-phosphate dehydrogenase-encoding gene from quail embryo fibroblasts In: Gene 128, 1993, S. 269-72.